View Article

Abstract

Heart failure management frequently relies on diuretic therapy to alleviate congestion and optimize volume status. Loop diuretics, such as furosemide and torsemide, act on the Na?–K?–2Cl? cotransporter in the loop of Henle and provide rapid, potent natriuresis. However, prolonged use may lead to electrolyte imbalance, neurohormonal activation, and diuretic resistance. Potassium-sparing diuretics, including aldosterone antagonists (spironolactone, eplerenone, finerenone) and ENaC blockers (amiloride, triamterene), act distally to conserve potassium and counteract aldosterone-driven sodium retention. When used together, these agents provide complementary effects. loop diuretics achieve effective decongestion while MRAs improve survival by mitigating cardiac remodeling. Major trials such as RALES and EPHESUS have established the mortality benefit of MRAs in heart failure. Careful monitoring of renal function and electrolytes remains essential to balance efficacy and safety.

Keywords

Loop diuretics, Potassium-sparing diuretics, Heart failure, Aldosterone antagonism, Diuretic resistance, Electrolyte imbalance, Combination therapy, Clinical outcomes, Pharmacological comparison.

Introduction

Heart failure (HF) is a progressive clinical syndrome resulting from structural or functional impairment of ventricular filling or ejection, leading to inadequate cardiac output to meet metabolic demands (3). The disease remains a major cause of morbidity and mortality worldwide, contributing to substantial healthcare expenditure and frequent hospital readmissions (4). Despite advances in neurohormonal blockade and device therapy, fluid retention and congestion remain dominant symptoms requiring pharmacologic diuresis (2).

The pathophysiology of congestion in HF is multifactorial. Elevated venous pressures, renal hypoperfusion, and neurohormonal activation particularly of the renin–angiotensin–aldosterone system (RAAS) and sympathetic nervous system lead to sodium and water retention (6). Diuretics correct volume overload by promoting urinary sodium excretion, thereby reducing preload, pulmonary capillary wedge pressure, and systemic edema (5). Among the diuretic classes, loop diuretics (e.g., furosemide, bumetanide, torsemide) are most frequently employed due to their potent natriuretic effect, rapid onset, and flexibility in both intravenous and oral administration (3). However, chronic loop-diuretic exposure can trigger compensatory neurohormonal activation, diuretic resistance, and electrolyte imbalance (1).

In contrast, potassium-sparing diuretics, primarily mineralocorticoid receptor antagonists (MRAs) offer complementary benefits. By inhibiting aldosterone’s action at the distal nephron, MRAs such as spironolactone, eplerenone, and finerenone mitigate potassium loss and counter maladaptive cardiac remodeling (9). In large clinical trials, MRAs have demonstrated mortality and morbidity reduction in both heart failure with reduced ejection fraction (HFrEF) and preserved ejection fraction (HFpEF) (10).

This review compares loop and potassium-sparing diuretics in detail, examining their mechanisms, pharmacodynamics, pharmacokinetics, clinical evidence, adverse-effect profiles, and roles in current HF management. It integrates evidence from key trials such as RALES, TOPCAT, DOSE, TRANSFORM-HF, and EMPHASIS-HF, alongside emerging insights from finerenone and SGLT2-inhibitor trials (7).

2. Pathophysiology of Fluid Retention in Heart Failure

In heart failure (HF), a decline in cardiac output initiates several compensatory neurohormonal responses aimed at preserving systemic perfusion. Prominently, the renin–angiotensin–aldosterone system (RAAS) becomes excessively activated, leading to sodium and water retention and increased systemic vascular resistance (11–13). Aldosterone, a key component of this pathway, enhances sodium reabsorption in the distal convoluted tubule and collecting duct while also inducing myocardial fibrosis, endothelial dysfunction, and ventricular remodeling, all of which worsen disease progression (14,15).

Simultaneously, the sympathetic nervous system (SNS) is upregulated, causing renal vasoconstriction and stimulating additional renin release, thereby further potentiating RAAS activation (12,13). The combination of neurohormonal vasoconstriction and renal sodium retention increases both preload and afterload, perpetuating congestion and fluid accumulation (16,17).

Diuretic therapy interrupts this maladaptive cycle by reducing extracellular fluid volume, lowering venous pressures, and improving clinical symptoms such as dyspnea and fatigue (18). However, excessive or aggressive diuresis may result in intravascular volume depletion, hypotension, renal impairment, and electrolyte imbalances. Hence, the optimal diuretic regimen requires careful balancing between symptomatic relief and hemodynamic stability,  challenge especially relevant when combining loop and potassium-sparing diuretics (9,20).

3. Mechanism of Action and Pharmacology of Loop Diuretics

3.1 Site and Mechanism of Action

Loop diuretics act principally at the thick ascending limb (TAL) of the loop of Henle. There, the luminal epithelial cells express the sodium-potassium-2-chloride cotransporter (NKCC2, gene SLC12A1) on the apical (luminal) membrane, which mediates the electroneutral uptake of Na?, K? and 2 Cl? from the tubular lumen into the cell.(21)
By inhibiting NKCC2, loop diuretics block approximately 25 % (or more, in certain physiologic states) of the filtered sodium load that would otherwise be reabsorbed at that site.(22)
The mechanism may be outlined as follows:

  • Blockade of NKCC2 → reduced Na?, K?, and Cl? reabsorption in the TAL.(23)
  • Increased delivery of sodium (and chloride) to the distal nephron segments.(24)
  • The TAL generates the cortico-medullary osmotic gradient (via active solute reabsorption) which is essential for water reabsorption in the collecting duct; inhibition of solute reabsorption diminishes the medullary interstitial hypertonicity, thus impairing water reabsorption and increasing free water (hypotonic) excretion. (24)
  • Inhibition of the K? recycling via the ROMK channel and resulting diminished positive luminal transepithelial voltage (normally about +10 mV) reduces paracellular reabsorption of Ca²? and Mg²?.(24)
  • Because the TAL is responsible for a large fraction of sodium reabsorption in the nephron, loop diuretics produce a strong natriuretic and diuretic effect (hence the term “high-ceiling” diuretics). (25)

In the context of heart failure (HF), this profound natriuresis and diuresis is exploited to relieve volume overload (pulmonary and systemic congestion) by enhancing sodium and fluid excretion and reducing intravascular and interstitial volume.

3.2 Pharmacokinetics and Onset

  • Furosemide remains the most widely used loop diuretic. Its oral bioavailability is highly variable (10 %–100 %, average ~50 %) owing to differences in absorption, especially in states of gut oedema or low perfusion.(26) When given orally, onset is typically within 30–60 minutes; when given intravenously onset may occur in ~5 minutes.(27)
  • Torsemide has much higher (≈80–90 % or more) and more predictable oral bioavailability, and a longer half-life (≈3–4 hours or more) compared with furosemide; this enables a more sustained natriuretic effect and once-daily or less frequent dosing in some patients.(28)
  • Bumetanide is highly potent (often cited as ~40 × potency of furosemide), with more predictable absorption and less inter-patient variability.(29)

Other pharmacokinetic considerations: loop diuretics are highly albumin-bound, secreted into the proximal tubular fluid via organic anion transporters (OATs), and require delivery to their tubular lumen site of action; hypoalbuminaemia, proximal tubular dysfunction and reduced renal perfusion can reduce drug delivery. (30)

3.3 Pharmacodynamic Variability

The natriuretic/diuretic response to loop diuretics in HF (and other conditions) is subject to considerable inter- and intra-patient variability, due to factors such as:

  • Intestinal oedema (in congested HF) reducing oral absorption of drug.
  • Reduced renal perfusion, low glomerular filtration rate, or proximal tubular secretion leading to decreased drug delivery to the TAL.(31)
  • High plasma protein binding and hypoalbuminaemia (less free drug available). (32)
  • Pharmacogenomic variation and transporter regulation (e.g., OATs, NKCC2 expression, trafficking) may influence response. (33)

Development of diuretic resistance: with repeated loop diuretic use, adaptations occur  hypertrophy of the distal convoluted tubule (DCT), up-regulation of the Na-Cl cotransporter (NCC) and epithelial sodium channel (ENaC) in the distal nephron, increased distal sodium reabsorption (“braking phenomenon”), and activation of the renin-angiotensin-aldosterone system (RAAS) and sympathetic nervous system. (34) Thus, even if the TAL is blocked, sodium reabsorption downstream (in the DCT and collecting tubule) can blunt the overall natriuretic effect. This explains why loop diuretic monotherapy may become less effective over time in congestive states. (35)

3.4 Clinical Utility

Loop diuretics serve as first-line therapy for relief of congestion and dyspnoea in patients with HF. In acute decompensated heart failure (ADHF), intravenous loop diuretics are preferred for rapid decongestion. The landmark DOSE trial (Diuretic Optimization Strategies Evaluation) in 2011 compared high-dose versus low-dose and bolus versus continuous infusion of IV furosemide (in 308 patients) and found that while there was no significant difference in the primary composite end-points (change in creatinine, worsening renal function), the high-dose strategy resulted in greater symptom relief (e.g., dyspnoea) at 72 h without significant worsening of renal function. (36) In the outpatient (or post-discharge) context, the TRANSFORM?HF trial (2,859 patients) compared torsemide versus furosemide after hospitalization for HF and found no statistically significant difference in all-cause mortality or all-cause hospitalization between the two diuretics over a median ~17.4 months follow-up. (37) Thus, in clinical practice, while torsemide and bumetanide may offer pharmacokinetic advantages, furosemide remains the most used agent. The choice often depends on patient factors (kidney function, absorption, prior response) and practical considerations (cost, availability, local formulary). (38)

4. Mechanism and Pharmacology of Potassium-Sparing Diuretics

4.1 Classification and mechanism

Potassium-sparing diuretics act on the late distal tubule and collecting duct to reduce sodium reabsorption and therefore blunt the luminal electrochemical gradient that drives potassium and hydrogen ion secretion. They fall into two mechanistic classes:

Mineralocorticoid receptor antagonists (MRAs). steroidal MRAs (spironolactone, eplerenone) and non-steroidal MRAs (finerenone). MRAs competitively block aldosterone binding to the intracellular mineralocorticoid receptor (MR) in principal cells. This prevents aldosterone-driven transcriptional upregulation of apical epithelial sodium channels (ENaC) and basolateral Na?/K?-ATPase, reducing net Na? reabsorption and K? secretion.

ENaC blockers. amiloride and triamterene directly inhibit the epithelial sodium channel (ENaC) on the apical membrane of principal cells, producing natriuresis and reducing the lumen-to-cell Na? gradient that normally promotes K? secretion through ROMK channels. ENaC blockers therefore conserve potassium by a direct channel blockade rather than hormone receptor antagonism.

Clinical consequences of these mechanisms:

  • MR blockade reduces aldosterone-mediated fibrosis, inflammation, and remodeling in myocardium and kidney in addition to producing a diuretic / potassium-sparing effect. (39)
  • ENaC blockade produces a milder natriuretic effect than loop or thiazide diuretics but is useful when potassium preservation is needed. (40)

4.2 Pharmacokinetics

Spironolactone is lipophilic and is rapidly metabolized in the liver to several active metabolites (notably canrenone and 7-α-thiomethylspironolactone). While parent spironolactone has a short plasma half-life (~1.4–1.5 hours), its active metabolites have much longer half-lives (commonly reported in the ~13–20 hour range), which account for the drug’s prolonged pharmacodynamic effect. (41)

Eplerenone is a steroidal but more selective MRA with far lower affinity for androgen and progesterone receptors than spironolactone; this receptor selectivity explains the reduced sex-hormone related adverse effects (e.g., gynecomastia) seen with eplerenone compared with spironolactone. Eplerenone’s pharmacokinetics allow twice-daily or once-daily dosing depending on indication and renal function. (42)

Finerenone is a non-steroidal MRA with a distinct receptor-binding profile and more balanced tissue distribution between heart and kidney (described as improved cardiorenal selectivity). Clinical programs (FIDELIO-DKD, FIGARO-DKD) demonstrated finerenone’s efficacy for cardiorenal endpoints and a tolerability profile that differs from steroidal MRAs (although hyperkalemia risk remains and must be monitored). (43) Dose adjustments and monitoring: all MRAs require renal function and serum potassium monitoring during initiation and up-titration; pharmacokinetic differences (metabolite half-lives, CYP interactions) should guide drug selection in patients on polypharmacy. (44)

4.3 Clinical role and evidence

HFrEF (heart failure with reduced ejection fraction). MRAs are core components of guideline-directed medical therapy (GDMT). The RALES trial (spironolactone, 1999) showed marked reductions in mortality and hospitalizations in severe HFrEF when low-dose spironolactone (25 mg/day) was added to standard therapy. (45)

Post-MI and milder HFrEF — EPHESUS (eplerenone post-MI) and EMPHASIS-HF (eplerenone in mild systolic HF) demonstrated reductions in mortality and HF hospitalization with eplerenone in their respective populations, establishing eplerenone as an evidence-based alternative to spironolactone in appropriate patients. (46)

HFpEF (heart failure with preserved ejection fraction). The TOPCAT trial tested spironolactone in HFpEF and found heterogeneity by region (notably differences between Eastern European sites and the rest of the study population). While the overall primary endpoint was not uniformly positive, analyses suggested reductions in HF hospitalization in some subgroups; the trial highlighted issues of enrollment, adherence, and regional differences that complicate interpretation. (47)

Finerenone in CKD and CV risk.  FIDELIO-DKD and FIGARO-DKD programs (summarized in NEJM and specialist reviews) showed that finerenone reduces cardiorenal events in patients with chronic kidney disease and type 2 diabetes, broadening MRA use into cardiorenal protection beyond classic HFrEF indications. (48)

Managing hyperkalemia and enabling continued MRA use

Hyperkalemia is the principal adverse effect limiting MRA use or up-titration. Two contemporary approaches to enable or maintain MRAs in patients at risk for hyperkalemia are:

  1. Use of ENaC blockers (amiloride, triamterene) as adjuncts in selected cases to conserve potassium (but these do not prevent MRA-related hyperkalemia and should be used cautiously and with monitoring). (49)
  2. Oral potassium binders patiromer and sodium zirconium cyclosilicate (SZC, formerly ZS-9) have been evaluated as strategies to lower serum potassium and allow initiation/optimization of RAASi/MRA therapy:
    • The DIAMOND and other patiromer studies/programs demonstrated that patiromer can maintain lower potassium and facilitate optimization/continuation of RAASi therapy in HFrEF patients with prior hyperkalemia. (50)
    • Trials and analyses of sodium zirconium cyclosilicate (ZS-9 / SZC) similarly show rapid potassium lowering and maintenance of normokalemia; recent trials (e.g., REALIZE-K / reports) have evaluated whether SZC permits safe spironolactone optimization in HFrEF patients with hyperkalemia. These data support the concept that potassium binders can enable guideline-recommended MRA dosing in patients otherwise limited by recurrent hyperkalemia. (51)
    • Practical point: although potassium binders can enable MRA therapy in many patients, clinicians must still monitor serum potassium and renal function frequently during initiation and titration; the benefit of enabling full GDMT must be weighed against costs, adverse effects, and individual patient risk. (52)

4.4 Key adverse effects and interactions

  • Hyperkalemia: the main safety concern with MRAs; risk increases with CKD, older age, diabetes, and concurrent RAAS inhibitors. Frequent monitoring is mandatory. (53)
  • Endocrine effects: spironolactone (less so eplerenone) is associated with anti-androgenic/progestational side effects (gynecomastia, impotence, menstrual irregularities) due to off-target receptor interactions. Eplerenone’s greater selectivity reduces these effects. (54)
  • Drug interactions: MRAs and potassium binders interact pharmacodynamically with other RAAS inhibitors and with drugs affecting renal potassium handling. Consider drug–drug interactions and CYP pathways (particularly for spironolactone/eplerenone metabolism) when prescribing. (55)

5. Table: Comparative Pharmacological and Clinical Characteristics of Loop and Potassium-Sparing Diuretics

Parameter

Loop Diuretics (e.g., furosemide, bumetanide, torsemide)

Potassium-Sparing Diuretics (MRAs e.g., spironolactone, eplerenone; ENaC blockers e.g., amiloride, triamterene)

Primary site & mechanism

Thick ascending limb of Henle — inhibit the Na?–K?–2Cl? (NKCC2) cotransporter → large natriuresis and loss of concentrating ability. (56)

Late distal tubule / cortical collecting duct — either block aldosterone receptor (mineralocorticoid receptor antagonists, MRAs) or directly block ENaC on principal cells → modest natriuresis, K? retention. (57)

Potency (approx. % filtered Na? inhibited)

High — loops block a large fraction of Na? reabsorption in TAL (TAL accounts for ~20–25% of filtered Na?; loops produce substantial natriuresis). (58)

Low — ENaC inhibitors account for ~2–3% of filtered Na? (weak natriuretic effect); MRAs act by antagonizing aldosterone-mediated Na? reabsorption (also modest natriuresis). (59)

Onset & duration

Rapid onset (IV: minutes; oral: 30–60 min), relatively short duration (depends on agent: furosemide shorter than torsemide). (60)

Slower onset — ENaC blockers hours; MRAs often require days (because antagonizing aldosterone-driven transcriptional effects takes time). (61)

Effect on potassium

Promotes K? loss (hypokalemia risk) — increases distal Na? delivery and K? secretion. (62)

Conserves K? — risk of hyperkalemia, especially with MRAs or when combined with RAS inhibitors or renal impairment. (63)

Effect on other electrolytes / minerals

Causes Mg²? wasting, Ca²? excretion (can lower Mg, can increase urinary Ca²?), may produce metabolic alkalosis. Ototoxicity at high doses or when combined with other ototoxins. (64)

Tend to be Mg-sparing (ENaC blockers) and have neutral/beneficial effects on Mg; MRAs may affect endocrine side effects (e.g., spironolactone). Monitor K?/creatinine. (65)

Major adverse effects (typical)

Hypokalemia, hypomagnesemia, volume depletion, renal impairment if overdiuresis, ototoxicity (high IV doses or rapid infusion). (66)

Hyperkalemia (MRAs & ENaC blockers), gynecomastia/impotence (spironolactone), endocrine effects (MRAs), metabolic effects (rare for ENaC blockers). (67)

Mortality / outcome data

Primarily symptomatic relief (volume removal); no clear mortality benefit from loop diuretics alone in chronic HF — used for symptom and congestion control. Key strategy trials examine dosing/administration (e.g., DOSE). (68)

MRAs (spironolactone, eplerenone, finerenone) have demonstrated mortality and morbidity benefits in large HF trials (e.g., RALES, EMPHASIS-HF); MRAs are guideline-recommended in appropriate HF patients. TOPCAT studied HFpEF with mixed results by region. (69)

Representative major trials

DOSE (dosing strategies for IV loop diuretics in acute decompensated HF); TRANSFORM-HF compared torsemide vs furosemide strategies. (70)

RALES (spironolactone in severe HFrEF), EMPHASIS-HF (eplerenone in mild HF), TOPCAT (spironolactone in HFpEF). (71)

Typical clinical uses

Rapid decongestion in acute decompensated HF, edema from renal failure/cirrhosis, pulmonary edema; preferred when brisk natriuresis required. (72)

Adjunct therapy to prevent remodeling and improve survival in HFrEF (MRAs); correct hypokalemia from other diuretics or as potassium-sparing adjunct (ENaC blockers); treatment of primary hyperaldosteronism (MRAs). (73)

Monitoring & cautions

Monitor volume status, electrolytes (K?, Mg²?), renal function; adjust dose in renal impairment; beware diuretic resistance and need for sequential nephron blockade. (74)

Monitor K? and renal function closely (especially when combined with ACEi/ARB/ARNI or in CKD); avoid or reduce dose if baseline hyperkalemia or severe renal impairment. Watch for endocrine side effects with spironolactone. (75)

Common combination strategies

Often combined with a potassium-sparing agent (MRA or amiloride) to reduce hypokalemia; sequential nephron blockade (loop + thiazide) for diuretic resistance. (76)

Used with loop diuretics to maintain potassium and reduce arrhythmia risk; MRAs added to ACEi/ARB/ARNI for mortality benefit in HFrEF with appropriate monitoring. (77)

Short interpretive notes (key takeaways)

  • Use loop diuretics when you need rapid and powerful natriuresis and decongestion (acute HF, pulmonary edema), but monitor for electrolyte losses and renal effects. DOSE addressed infusion strategy and dosing intensity in acute decompensated HF. (78)
  • Potassium-sparing agents are weak natriuretics but valuable: ENaC blockers are used mainly to prevent hypokalemia, while MRAs provide proven morbidity/mortality benefits in HFrEF (RALES, EMPHASIS-HF) and are guideline-recommended in indicated patients, but they require careful K?/renal monitoring. (79)
  • Combining a loop with a potassium-sparing agent is common (symptom relief + K? protection), but watch for hyperkalemia when MRAs are used with RAS inhibitors or in CKD. (80)

6. Clinical evidence and major trials

6.1 RALES (1999) — Spironolactone in severe HFrEF

The Randomized Aldactone Evaluation Study (RALES) enrolled 1,663 patients with NYHA class III–IV heart failure and LVEF <35% and randomized them to spironolactone (typically 25 mg daily) versus placebo on top of standard therapy. The trial was stopped early for benefit: spironolactone produced a large relative reduction in all-cause mortality (≈30%) and significantly fewer hospitalizations for heart failure. Hyperkalemia events were uncommon in the trial (clinically important hyperkalemia reported in a small percentage) but the publication and subsequent pharmacoepidemiology analyses stressed the importance of careful potassium/renal monitoring when MRAs are used in real-world practice. (79)

6.2 EPHESUS (2003) — Eplerenone after myocardial infarction with LV dysfunction

EPHESUS randomized patients with acute myocardial infarction complicated by left-ventricular dysfunction (LVEF ≤40%) and clinical heart-failure or diabetes to eplerenone versus placebo, initiated early after the index event (within days). Eplerenone reduced all-cause mortality (relative reduction ≈15%) and sudden cardiac death, establishing that mineralocorticoid-receptor antagonism provides a survival advantage when started soon after an ischemic insult in patients with LV dysfunction. The trial supported extending MRA use beyond advanced chronic HFrEF into the early post-MI population with systolic dysfunction. (80)

6.3 EMPHASIS-HF (2011) — Eplerenone in milder HFrEF (NYHA II)

EMPHASIS-HF enrolled 2,737 patients with symptomatic HFrEF (NYHA class II) and randomized eplerenone versus placebo on top of guideline therapy. The study reported a marked reduction in the primary composite of cardiovascular death or heart-failure hospitalization (≈37% relative reduction) and consistent benefit across age and renal-function subgroups. EMPHASIS-HF helped cement the role of MRAs as part of foundational therapy for symptomatic HFrEF, not only in advanced disease.

6.4 TOPCAT (2014) — Spironolactone in HFpEF

The TOPCAT trial tested spironolactone in 3,445 patients with heart failure and preserved LVEF (≥45%). The overall trial did not meet its primary composite endpoint in the entire cohort; however, important regional heterogeneity was observed. patients enrolled in the Americas experienced significant reductions in heart-failure hospitalizations and trends toward mortality benefit, whereas other regions did not. TOPCAT highlighted challenges in trial conduct, potential differences in patient populations and adherence, and left open questions about patient selection and who  if anyone  with HFpEF should receive MRAs. (81)

6.5 DOSE (2011) — Strategies for IV furosemide in acute decompensated HF

The DOSE trial randomized 308 patients with acute decompensated heart failure to either a low or a high initial IV furosemide dose (and to bolus versus continuous infusion). High-dose therapy (approximately 2.5× the patient’s usual oral dose) produced greater symptom relief and more natriuresis/diuresis at 72 hours without a clinically important penalty in renal outcomes; continuous infusion offered no clear advantage over bolus dosing in the trial’s endpoints. DOSE remains a practical reference when choosing initial loop-diuretic dosing strategies in ADHF. (82)

6.6 TRANSFORM-HF (2023) — Torsemide versus furosemide after hospitalization

TRANSFORM-HF was a large pragmatic randomized trial comparing torsemide with furosemide in patients discharged after hospitalization for heart failure. At 12 months there was no statistically significant difference in all-cause mortality between the two arms, although secondary and mechanistic analyses have pointed to torsemide’s more predictable pharmacokinetics and possible antifibrotic properties; overall, TRANSFORM-HF does not support routine replacement of furosemide by torsemide solely to improve survival. (83)

6.7 ADVOR (2022) — Acetazolamide as adjunctive therapy in ADHF

The ADVOR trial evaluated adding acetazolamide (a proximal tubular carbonic anhydrase inhibitor) to loop-diuretic therapy in patients with acute decompensated heart failure and demonstrated greater rates of successful decongestion and shorter length of hospital stay without major safety signals. ADVOR provided randomized evidence supporting the strategy of sequential nephron blockade (combining diuretics that act at different nephron sites) to overcome diuretic resistance and enhance early decongestion. (84)

6.8 Meta-analyses, pooled evidence and guideline implications

Multiple pooled analyses and recent systematic reviews confirm that steroidal MRAs (spironolactone, eplerenone) materially reduce mortality and heart-failure hospitalizations in HFrEF, with relative mortality reductions on the order of ~25–35% in pooled estimates; individual patient-level and contemporary meta-analyses also demonstrate benefit across many clinical subgroups while underscoring the real-world need to monitor potassium and renal function because of an increased risk of hyperkalemia in certain populations. In contrast, randomized evidence for loop diuretics shows clear and consistent symptomatic benefit and relief of congestion but  unlike MRAs.  no trial has demonstrated a mortality benefit attributable to loop diuretic choice per se. Current major international guidelines therefore recommend loop diuretics as first-line therapy for congestion and give Class I recommendation to MRAs for eligible patients with HFrEF (with monitoring), while recommendations in HFpEF remain nuanced and depend on trial subgroup signals and patient characteristics. (85)

Practical takeaways from the trials and pooled data

  • MRAs (spironolactone, eplerenone) have robust randomized-trial evidence of mortality and hospitalization benefit in HFrEF (RALES, EPHESUS, EMPHASIS-HF) and are Class I-recommended in most guideline algorithms for eligible patients, with careful monitoring for hyperkalemia and renal dysfunction. (86)
  • Loop diuretics are indispensable for symptomatic control of congestion and should be dosed aggressively when clinically indicated (DOSE), with sequential nephron blockade (e.g., addition of acetazolamide, thiazides, or MRAs) considered for diuretic resistance (ADVOR and practice reviews). (87)
  • Choice between torsemide and furosemide appears unlikely to change mortality (TRANSFORM-HF), though local availability, pharmacokinetic preferences, and patient response guide practice. (88)

7. Adverse effects and monitoring

7.1 Loop diuretics (e.g., furosemide, bumetanide, torsemide)

Key adverse effects & mechanisms

  • Electrolyte disturbances — Hypokalemia and hypomagnesemia are common because loop diuretics abolish the lumen-positive potential in the thick ascending limb and increase distal sodium delivery, both of which drive K? and Mg²? loss. Hyponatremia may occur with excessive free-water intake or very high doses. (89)
  • Volume depletion and renal dysfunction — Excessive diuresis can cause intravascular volume depletion, symptomatic hypotension and prerenal azotemia; renal function should be interpreted in the clinical context (decongestion vs. true kidney injury). (90)
  • Ototoxicity — Loop diuretics can cause reversible or (rarely) permanent hearing loss/tinnitus; risk increases with high IV bolus doses, very rapid administration, renal impairment, and co-administration of other ototoxins (notably aminoglycosides). Monitor for auditory symptoms when these risk factors are present. (91)
  • Metabolic effects — Hyperuricemia (precipitating gout) and small effects on glucose tolerance are recognised, particularly with chronic or high-dose therapy. (92)

Monitoring recommendations (practical points)

  • Baseline: weight, blood pressure, serum electrolytes (Na?, K?, Mg²?), urea/creatinine (or eGFR).
  • After dose initiation or upward titration: check electrolytes and renal function within 48–72 hours (or sooner if symptomatic), then again at 1 week if there are risk factors (elderly, CKD, concomitant RAAS blockade). Adjust dose if there is symptomatic hypotension, large rise in creatinine, or clinically important electrolyte changes. (93)
  • Ongoing: monitor weights (daily while adjusting dose), and periodic electrolytes and renal function (frequency individualized  more frequent during active titration or with intercurrent illness). (94)

When to worry & actions

  • Symptomatic hypotension, rising creatinine with clinical signs of hypovolaemia → reduce/hold dose, replete volume as indicated, and reassess.
  • New or worsening hearing symptoms during high-dose IV diuretics, or concomitant aminoglycoside therapy → stop/hold dose and evaluate audiology. (95)

7.2 Potassium-sparing diuretics (MRAs: spironolactone, eplerenone, finerenone; ENaC blockers)

Key adverse effects & mechanisms

  • Hyperkalemia (major safety issue) — MRAs reduce urinary K? excretion; risk is potentiated by CKD, diabetes, high baseline K?, and co-prescription of ACEi/ARB/ARNI or heparin. Hyperkalemia can be life-threatening; clinicians must monitor and manage proactively. (96)
  • Endocrine effects — Spironolactone has off-target antiandrogen and progestin effects that can cause gynecomastia, breast tenderness, and menstrual irregularities. Eplerenone and finerenone are more selective for the mineralocorticoid receptor and have substantially lower rates of these endocrine adverse effects. (97)
  • Renal effects — Small, usually transient rises in creatinine may occur after initiation; a rise alone does not always mandate stopping therapy if the patient is clinically stable  evaluate trend, symptoms, and magnitude. (98)

Monitoring schedule (practical, guideline-based)

  • Baseline: serum K? and creatinine/eGFR before starting.
  • Early follow-up: check serum K? and creatinine within 72 hours to 1 week after initiation or dose increase, this captures most early hyperkalemia and renal changes. (99)
  • Short-term: then monthly for the first 3 months.
  • Long-term: if stable, monitor every 3–4 months (some guidance recommends every 3–6 months depending on comorbidity and concomitant therapies). These schedules are in major HF guidance documents and reflect trial protocols and safety analyses. (100)

Action thresholds & practical management

  • If K? 5.5–5.9 mmol/L: consider halving the MRA dose (or interval dosing), review and correct reversible contributors (diet, potassium supplements, other drugs), and repeat labs frequently. Use potassium binders if recurrent or persistent hyperkalemia is limiting guideline-directed therapy. (101)
  • If K? ≥ 6.0 mmol/L: withhold MRA, treat hyperkalemia per local protocols, and reassess (many guidelines recommend re-checking 48–72 hours after holding and restarting only when K? is safely lower). (102)
  • If creatinine/eGFR declines substantially (e.g., >30% rise in creatinine or large eGFR drop), reassess volume status, concomitant nephrotoxins, and consider dose reduction/temporary discontinuation while investigating. Small rises that occur with decongestion or RAAS blockade are not always a reason for permanent cessation. (103)

Practical tips for clinicians

  • Always check for drug interactions and cumulative hyperkalemia risk (ACEi/ARB/ARNI, NSAIDs, trimethoprim, heparin, potassium supplements).
  • Educate patients to report dizziness, palpitations, muscle weakness, new breast tenderness (spironolactone), or hearing changes (loops).
  • Consider newer potassium binders (when available) to allow continuation of guideline-directed MRAs in selected patients with recurrent hyperkalemia weigh benefits vs. cost and long-term data. (104)

8. Combination and Sequential Nephron Blockade

Co-administration of loop diuretics with distal-acting agents (thiazides or thiazide-like agents such as metolazone) or with proximal/alternate-segment blockers (carbonic anhydrase inhibitors such as acetazolamide) produces sequential nephron blockade: loops acutely inhibit NKCC2 in the thick ascending limb, thiazide-type agents inhibit the distal Na?–Cl? cotransporter, and acetazolamide reduces proximal tubular bicarbonate-linked sodium reabsorption. When used together, these drugs act on complementary nephron segments to overcome adaptive sodium reabsorption and diuretic resistance, producing larger natriuresis and greater net fluid loss than monotherapy. (105)

Clinical trials and systematic reviews show that:

  • Metolazone added to loop diuretics is an effective and widely used strategy in refractory congestion, increasing natriuresis and weight loss; the pooled literature finds benefit for decongestion but highlights frequent electrolyte disturbances (hypokalemia, hyponatremia) and occasional worsening renal function, requiring close monitoring. (106)
  • Acetazolamide added to standardized IV loop diuretics improved early decongestion and shortened length of stay in the randomized ADVOR trial, supporting proximal-segment blockade as a useful adjunct in acute decompensated HF with volume overload. Safety signals were acceptable when electrolytes and acid-base status were monitored. (107)

Practical points and monitoring:

  • Start adjunctive agents at low doses and reassess natriuresis/urine output frequently (spot urine Na? or short timed collections), serum electrolytes, and creatinine; expect and prevent hypokalemia (replace potassium or use an MRA when appropriate) and metabolic alkalosis or acidosis depending on the combination. (108)
  • Use sequential blockade when loop responses are inadequate (poor natriuresis despite escalating loop doses) rather than reflexively increasing loop doses, because combination therapy can be more effective for mobilizing interstitial fluid and shortening hospital stay. (109)

Overall, combination/sequential blockade improves short-term decongestion durability and symptom relief. Meta-analytic data suggest improved fluid removal and symptom scores; when carefully titrated and monitored, combination strategies have not been consistently associated with increased mortality, though they do increase certain adverse events (electrolyte abnormalities, transient renal dysfunction), emphasizing the need for protocolized laboratory surveillance. (110)

9. Future Directions and Emerging Therapies

9.1 Finerenone and Non-Steroidal MRAs

Finerenone is a non-steroidal mineralocorticoid receptor antagonist with greater receptor selectivity and a different pharmacologic profile than spironolactone/eplerenone. Large trials in patients with type 2 diabetes and chronic kidney disease (FIDELIO-DKD, FIGARO-DKD) showed reductions in cardiorenal outcomes and lower rates of heart-failure hospitalization versus placebo; hyperkalemia risk exists but appears numerically lower or more manageable than with older MRAs in some analyses. Ongoing and post-hoc analyses are evaluating finerenone’s direct role across the heart-failure ejection-fraction spectrum. (111)

9.2 SGLT2 Inhibitors as Diuretic Adjuncts

SGLT2 inhibitors (dapagliflozin, empagliflozin) produce modest natriuresis by inhibiting proximal tubular reabsorption of glucose and sodium, promoting osmotic diuresis and favourable intrarenal haemodynamics. Large heart-failure outcome trials (DAPA-HF, EMPEROR program and subsequent HFpEF/HFmrEF trials) demonstrated consistent reductions in heart-failure hospitalizations and improvement in symptoms and outcomes irrespective of background diuretic dose or diabetes status. Integration of SGLT2 inhibitors with loop + MRA strategies is now standard in many guideline pathways as a multitarget approach to reduce congestion and improve prognosis. (112)

9.3 Potassium Binders to Enable MRA Use

Oral potassium binders such as patiromer and sodium zirconium cyclosilicate (SZC, Lokelma) safely lower serum K? and have been shown to permit continuation or initiation of RAAS/MRA therapy in patients who would otherwise be excluded because of hyperkalemia risk. Randomized and long-term extension studies demonstrate prompt K? lowering and maintenance of normokalemia; these agents expand MRA eligibility and allow safer up-titration of guideline-directed therapy in patients with CKD or baseline hyperkalemia. Monitor for gastrointestinal adverse effects and drug-drug timing interactions. (113)

9.4 Personalized Diuretic Therapy: biomarkers & machine learning

Precision decongestion strategies are advancing along two complementary axes:

  1. Biomarker-guided titration. Spot urine sodium and short timed urinary sodium collections after a loop diuretic dose are increasingly validated as rapid biomarkers of natriuretic response; lower early urine Na? predicts poor diuretic response and worse outcomes, and natriuresis-guided protocols shorten length of stay in early trials. (114)
  2. Predictive modelling / machine learning. Several groups have built and externally validated ML models to predict diuretic resistance or insufficient natriuresis using routine clinical, laboratory and hemodynamic inputs; these models (and natriuretic response equations) can potentially personalize initial dosing, decide when to add sequential blockade, and reduce readmissions by optimizing early decongestion strategies. Ongoing prospective implementation work aims to embed these algorithms into electronic health records and natriuresis-guided care pathways. (115)

Taken together, the future is a multimodal approach: combine evidence-based agents (SGLT2i, MRAs/finerenone, loop diuretics), use potassium binders to permit full RAAS blockade when needed, and apply spot urine sodium + ML tools to guide when and which adjunctive diuretics to add all while maintaining tight electrolyte and renal monitoring to mitigate harm. (116)

CONCLUSION

Loop and potassium-sparing diuretics represent cornerstone therapies in heart failure, each targeting different nephron segments to achieve volume control and neurohormonal modulation. Their synergistic use enhances symptomatic relief and long-term outcomes, provided close monitoring prevents complications like hyperkalemia or renal impairment. Rational combination therapy guided by evidence-based protocols optimizes decongestion, preserves potassium balance, and improves survival in patients with chronic heart failure.

REFERENCES

  1. Pitt B, Zannad F, Remme WJ, et al. (1999). The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure. New England Journal of Medicine, 341(10), 709-717.
  2. Felker GM, Leimberger JD, Califf RM, et al. (2007). Relation between dose of loop diuretics and outcomes in a heart-failure population: results of the ESCAPE trial. European Journal of Heart Failure, 9(10), 1064-1069.
  3. Felker GM, Ellison DH, Mullens W, Cox ZL, Testani JM. (2020). Diuretic Therapy for Patients With Heart Failure: JACC State-of-the-Art Review. Journal of the American College of Cardiology, 75(10), 1178-1195.
  4. Testani JM, et al. (2024). Diuretic Treatment in Heart Failure: A Practical Guide for Clinicians. Frontiers in Cardiovascular Medicine, 11, 11313642.
  5. Mullens W, et al. (2024). The Diuretic Optimisation Strategies Evaluation (DOSE) trial: Loop diuretic strategies in acute decompensated heart failure. European Heart Journal, 45(9), 10924023.
  6. Greene SJ, Velazquez EJ, Anstrom KJ, et al. (2023). Effect of Torsemide vs Furosemide after Discharge on All-Cause Mortality in Patients Hospitalized with Heart Failure: The TRANSFORM-HF Randomized Clinical Trial. JAMA, 329(3), 214-223.
  7. Vardeny O, et al. (2025). Finerenone, Serum Potassium, and Clinical Outcomes in Heart Failure (FINEARTS-HF). JAMA Cardiology.
  8. Georgianos PI, et al. (2024). Mineralocorticoid Receptor Antagonism in Heart Failure. Journal of the American College of Cardiology: Heart Failure.
  9. Jhund PS, et al. (2024). Mineralocorticoid receptor antagonists in heart failure: systematic review and meta-analysis. The Lancet.
  10. Jhund PS, et al. (2024). Mineralocorticoid receptor antagonists in heart failure: systematic review and meta-analysis. The Lancet.
  11. Pfeffer MA, Braunwald E. (2016). Treatment of Heart Failure With Preserved Ejection Fraction: Reflections on Its Treatment With an Aldosterone Antagonist. JAMA Cardiology, 1(1), 7-8.
  12. Yancy CW, et al. Edema formation in congestive heart failure and the underlying mechanisms. Front Cardiovasc Med. 2022.
  13. Triposkiadis F, et al. Sympathetic nervous system activation and heart failure. Curr Heart Fail Rep. 2020;17(3):191–200.
  14. Roh J, et al. Neurohormonal activation in heart failure with reduced ejection fraction. Heart Fail Rev. 2017;22(5):601–611.
  15. Rana I, et al. The renin–angiotensin–aldosterone system and myocardial remodeling. Front Physiol. 2023;14:1034170.
  16. Funder, J. W. (2010). Aldosterone and mineralocorticoid receptors in the cardiovascular system. Progress in Cardiovascular Diseases, 52(5), 393–400. https://doi.org/10.1016/j.pcad.2009.12.003
  17. Verbrugge FH, et al. Unveiling the systemic impact of congestion in heart failure. Card Fail Rev. 2024;10(1):e24.
  18. Schrier RW. Pathophysiology of sodium and water retention in heart failure. Cardiorenal Med. 2006;96(3–4):122–131.
  19. Francis GS, et al. Water and sodium regulation in heart failure. J Am Coll Cardiol. 2011;57(4):451–463.
  20. Ellison, D. H., & Felker, G. M. (2017). Diuretic treatment in heart failure. New England Journal of Medicine, 377(20), 1964–1975. https://doi.org/10.1056/nejmra1703100
  21. Schrier RW, et al. Complications of aggressive diuresis in decompensated heart failure. Cleve Clin J Med. 2006;73(Suppl 2):S2–S8.
  22. Gamba, G. (2023). From fish physiology to Human Disease: The discovery of the NCC, NKCC2, and the Cation-Coupled Chloride cotransporters. Kidney360, 5(1), 133–141. https://doi.org/10.34067/kid.0000000000000307
  23. Zacchia, M., Capolongo, G., Rinaldi, L., & Capasso, G. (2018). The importance of the thick ascending limb of Henle&rsquo;s loop in renal physiology and pathophysiology. International Journal of Nephrology and Renovascular Disease, Volume 11, 81–92. Https://doi.org/10.2147/ijnrd.s154000
  24. Huxel, C., Raja, A., & Ollivierre-Lawrence, M. D. (2023, May 22). Loop diuretics. StatPearls - NCBI Bookshelf. https://www.ncbi.nlm.nih.gov/books/NBK546656/?utm_source=chatgpt.com
  25. Yartsev, A. (n.d.). Furosemide. Deranged Physiology. https://derangedphysiology.com/main/cicm-primary-exam/renal-system/Chapter-022/furosemide?
  26. Shankar, S. S., & Brater, D. C. (2003). Loop diuretics: from the Na-K-2Cl transporter to clinical use. AJP Renal Physiology, 284(1), F11–F21. https://doi.org/10.1152/ajprenal.00119.2002
  27. Huxel, C., Raja, A., & Ollivierre-Lawrence, M. D. (2023, May 22). Loop diuretics. StatPearls - NCBI Bookshelf. https://www.ncbi.nlm.nih.gov/books/NBK546656/?utm_source=chatgpt.com
  28. Huxel, C., Raja, A., & Ollivierre-Lawrence, M. D. (2023b, May 22). Loop diuretics. StatPearls - NCBI Bookshelf. https://www.ncbi.nlm.nih.gov/books/NBK546656/?.com
  29. Buggey, J., Mentz, R. J., Pitt, B., Eisenstein, E. L., Anstrom, K. J., Velazquez, E. J., & O’Connor, C. M. (2015). A reappraisal of loop diuretic choice in heart failure patients. American Heart Journal, 169(3), 323–333. https://doi.org/10.1016/j.ahj.2014.12.009
  30. Wikipedia contributors. (2025, October 17). Bumetanide. Wikipedia. https://en.wikipedia.org/wiki/Bumetanide?
  31. Ellison, D. H. (2019). Clinical pharmacology in diuretic use. Clinical Journal of the American Society of Nephrology, 14(8), 1248–1257. https://doi.org/10.2215/cjn.09630818
  32. Practice Advisory [RETIRED]. (1996). Neurology, 47(3), 835–839. https://doi.org/10.1212/wnl.47.3.835
  33. Yartsev, A. (n.d.). Furosemide. Deranged Physiology. https://derangedphysiology.com/main/cicm-primary-exam/renal-system/Chapter-022/furosemide?
  34. Maskey, D., Pineda, J. G., & Ortiz, P. A. (2024). Update on NKCC2 regulation in the thick ascending limb (TAL) by membrane trafficking, phosphorylation, and protein-protein interactions. Frontiers in Physiology, 15. https://doi.org/10.3389/fphys.2024.1508806
  35. Rao, V. S., Planavsky, N., Hanberg, J. S., Ahmad, T., Brisco-Bacik, M. A., Wilson, F. P., Jacoby, D., Chen, M., Tang, W. W., Cherney, D. Z., Ellison, D. H., & Testani, J. M. (2017). Compensatory distal reabsorption drives diuretic resistance in human heart failure. Journal of the American Society of Nephrology, 28(11), 3414–3424. https://doi.org/10.1681/asn.2016111178
  36. Cox, Z. L., Rao, V. S., & Testani, J. M. (2022). Classic and novel mechanisms of diuretic resistance in cardiorenal syndrome. Kidney360, 3(5), 954–967. https://doi.org/10.34067/kid.0006372021
  37. Felker, G. M., Lee, K. L., Bull, D. A., Redfield, M. M., Stevenson, L. W., Goldsmith, S. R., LeWinter, M. M., Deswal, A., Rouleau, J. L., Ofili, E. O., Anstrom, K. J., Hernandez, A. F., McNulty, S. E., Velazquez, E. J., Kfoury, A. G., Chen, H. H., Givertz, M. M., Semigran, M. J., Bart, B. A., . . . O’Connor, C. M. (2011c). Diuretic Strategies in Patients with Acute Decompensated Heart Failure. New England Journal of Medicine, 364(9), 797–805. https://doi.org/10.1056/nejmoa1005419
  38. Mentz, R. J., Anstrom, K. J., Eisenstein, E. L., Sapp, S., Greene, S. J., Morgan, S., Testani, J. M., Harrington, A. H., Sachdev, V., Ketema, F., Kim, D., Desvigne-Nickens, P., Pitt, B., Velazquez, E. J., Adams, K. F., Bhatt, K., DeWald, T., Axsom, K. M., Murthy, S., . . . Smart, F. (2023c). Effect of Torsemide vs Furosemide After Discharge on All-Cause Mortality in Patients Hospitalized With Heart Failure. JAMA, 329(3), 214. https://doi.org/10.1001/jama.2022.23924
  39. Sica, D. A. (2015). Mineralocorticoid receptor antagonists for treatment of hypertension and heart failure. Methodist DeBakey Cardiovascular Journal, 11(4), 235. https://doi.org/10.14797/mdcj-11-4-235
  40. Sica, D. A. (2015). Mineralocorticoid receptor antagonists for treatment of hypertension and heart failure. Methodist DeBakey Cardiovascular Journal, 11(4), 235. https://doi.org/10.14797/mdcj-11-4-235
  41. Almajid, A. N., Patel, P., & Cassagnol, M. (2024, February 28). Amiloride. StatPearls - NCBI Bookshelf. https://www.ncbi.nlm.nih.gov/books/NBK542303/?
  42. ALDACTONE® (spironolactone) Clinical Pharmacology | Pfizer Medical - US. (n.d.). https://www.pfizermedical.com/aldactone/clinical-pharmacology?
  43. Takeda, Y. (2009). Effects of eplerenone, a selective mineralocorticoid receptor antagonist, on clinical and experimental salt-sensitive hypertension. Hypertension Research, 32(5), 321–324. https://doi.org/10.1038/hr.2009.29
  44. Pitt, B., Filippatos, G., Agarwal, R., Anker, S. D., Bakris, G. L., Rossing, P., Joseph, A., Kolkhof, P., Nowack, C., Schloemer, P., & Ruilope, L. M. (2021b). Cardiovascular Events with Finerenone in Kidney Disease and Type 2 Diabetes. New England Journal of Medicine, 385(24), 2252–2263. https://doi.org/10.1056/nejmoa2110956
  45. ALDACTONE® (spironolactone) Clinical Pharmacology Patient information | Pfizer Medical - US. (n.d.). https://www.pfizermedical.com/patient/aldactone/clinical-pharmacology?utm_source=chatgpt.com
  46. Pitt, B., Zannad, F., Remme, W. J., Cody, R., Castaigne, A., Perez, A., Palensky, J., & Wittes, J. (1999). The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure. New England Journal of Medicine, 341(10), 709–717. https://doi.org/10.1056/nejm199909023411001
  47. Pitt, B., Remme, W., Zannad, F., Neaton, J., Martinez, F., Roniker, B., Bittman, R., Hurley, S., Kleiman, J., & Gatlin, M. (2003). Eplerenone, a Selective Aldosterone Blocker, in Patients with Left Ventricular Dysfunction after Myocardial Infarction. New England Journal of Medicine, 348(14), 1309–1321. https://doi.org/10.1056/nejmoa030207
  48. Pitt, B., Pfeffer, M. A., Assmann, S. F., Boineau, R., Anand, I. S., Claggett, B., Clausell, N., Desai, A. S., Diaz, R., Fleg, J. L., Gordeev, I., Harty, B., Heitner, J. F., Kenwood, C. T., Lewis, E. F., O’Meara, E., Probstfield, J. L., Shaburishvili, T., Shah, S. J., . . . McKinlay, S. M. (2014). Spironolactone for Heart Failure with Preserved Ejection Fraction. New England Journal of Medicine, 370(15), 1383–1392. https://doi.org/10.1056/nejmoa1313731
  49. Pitt, B., Filippatos, G., Agarwal, R., Anker, S. D., Bakris, G. L., Rossing, P., Joseph, A., Kolkhof, P., Nowack, C., Schloemer, P., & Ruilope, L. M. (2021). Cardiovascular Events with Finerenone in Kidney Disease and Type 2 Diabetes. New England Journal of Medicine, 385(24), 2252–2263. https://doi.org/10.1056/nejmoa2110956
  50. Almajid, A. N., Patel, P., & Cassagnol, M. (2024, February 28). Amiloride. StatPearls - NCBI Bookshelf. https://www.ncbi.nlm.nih.gov/books/NBK542303/?
  51. Patiromer for the Management of Hyperkalemia in Subjects receiving RAASI for HFREF - American College of Cardiology. (2022, April 2). American College of Cardiology. https://www.acc.org/Latest-in-Cardiology/Clinical-Trials/2022/04/02/15/56/DIAMOND
  52. Anker, S. D., Kosiborod, M., Zannad, F., Piña, I. L., McCullough, P. A., Filippatos, G., Van Der Meer, P., Ponikowski, P., Rasmussen, H. S., Lavin, P. T., Singh, B., Yang, A., & Deedwania, P. (2015). Maintenance of serum potassium with sodium zirconium cyclosilicate (ZS?9) in heart failure patients: results from a phase 3 randomized, double?blind, placebo?controlled trial. European Journal of Heart Failure, 17(10), 1050–1056. https://doi.org/10.1002/ejhf.300
  53. Butler, J., Anker, S. D., Lund, L. H., Coats, A. J. S., Filippatos, G., Siddiqi, T. J., Friede, T., Fabien, V., Kosiborod, M., Metra, M., Piña, I. L., Pinto, F., Rossignol, P., Van Der Meer, P., Bahit, C., Belohlavek, J., Böhm, M., Brugts, J. J., Cleland, J. G. F., . . . Pitt, B. (2022). Patiromer for the management of hyperkalemia in heart failure with reduced ejection fraction: the DIAMOND trial. European Heart Journal, 43(41), 4362–4373. https://doi.org/10.1093/eurheartj/ehac401
  54. Sica, D. A. (2015). Mineralocorticoid receptor antagonists for treatment of hypertension and heart failure. Methodist DeBakey Cardiovascular Journal, 11(4), 235. https://doi.org/10.14797/mdcj-11-4-235
  55. Brown, N. J. (2003). Eplerenone. Circulation, 107(19), 2512–2518. https://doi.org/10.1161/01.cir.0000071081.35693.9a
  56. ALDACTONE® (spironolactone) Clinical Pharmacology Patient information | Pfizer Medical - US. (n.d.). https://www.pfizermedical.com/patient/aldactone/clinical-pharmacology?utm_source=chatgpt.com
  57. Felker, G. M., Lee, K. L., Bull, D. A., Redfield, M. M., Stevenson, L. W., Goldsmith, S. R., LeWinter, M. M., Deswal, A., Rouleau, J. L., Ofili, E. O., Anstrom, K. J., Hernandez, A. F., McNulty, S. E., Velazquez, E. J., Kfoury, A. G., Chen, H. H., Givertz, M. M., Semigran, M. J., Bart, B. A., . . . O’Connor, C. M. (2011). Diuretic Strategies in Patients with Acute Decompensated Heart Failure. New England Journal of Medicine, 364(9), 797–805. https://doi.org/10.1056/nejmoa1005419
  58. Zannad, F., McMurray, J. J., Krum, H., Van Veldhuisen, D. J., Swedberg, K., Shi, H., Vincent, J., Pocock, S. J., & Pitt, B. (2010). Eplerenone in Patients with Systolic Heart Failure and Mild Symptoms. New England Journal of Medicine, 364(1), 11–21. https://doi.org/10.1056/nejmoa1009492
  59. Huxel, C., Raja, A., & Ollivierre-Lawrence, M. D. (2023, May 22). Loop diuretics. StatPearls - NCBI Bookshelf. https://www.ncbi.nlm.nih.gov/books/NBK546656/
  60. Arumugham, V. B., & Shahin, M. H. (2023, May 29). Therapeutic uses of diuretic agents. StatPearls - NCBI Bookshelf. https://www.ncbi.nlm.nih.gov/books/NBK557838/
  61. Felker, G. M., Lee, K. L., Bull, D. A., Redfield, M. M., Stevenson, L. W., Goldsmith, S. R., LeWinter, M. M., Deswal, A., Rouleau, J. L., Ofili, E. O., Anstrom, K. J., Hernandez, A. F., McNulty, S. E., Velazquez, E. J., Kfoury, A. G., Chen, H. H., Givertz, M. M., Semigran, M. J., Bart, B. A., . . . O’Connor, C. M. (2011). Diuretic Strategies in Patients with Acute Decompensated Heart Failure. New England Journal of Medicine, 364(9), 797–805. https://doi.org/10.1056/nejmoa1005419
  62. Arumugham, V. B., & Shahin, M. H. (2023b, May 29). Therapeutic uses of diuretic agents. StatPearls - NCBI Bookshelf. https://www.ncbi.nlm.nih.gov/books/NBK557838/
  63. Huxel, C., Raja, A., & Ollivierre-Lawrence, M. D. (2023, May 22). Loop diuretics. StatPearls - NCBI Bookshelf. Retrieved October 30, 2025, from https://www.ncbi.nlm.nih.gov/books/NBK546656/
  64. Zannad, F., McMurray, J. J., Krum, H., Van Veldhuisen, D. J., Swedberg, K., Shi, H., Vincent, J., Pocock, S. J., & Pitt, B. (2010). Eplerenone in Patients with Systolic Heart Failure and Mild Symptoms. New England Journal of Medicine, 364(1), 11–21. https://doi.org/10.1056/nejmoa1009492
  65. Huxel, C., Raja, A., & Ollivierre-Lawrence, M. D. (2023b, May 22). Loop diuretics. StatPearls - NCBI Bookshelf. Retrieved October 30, 2025, from https://www.ncbi.nlm.nih.gov/books/NBK546656/
  66. Arumugham, V. B., & Shahin, M. H. (2023c, May 29). Therapeutic uses of diuretic agents. StatPearls - NCBI Bookshelf. https://www.ncbi.nlm.nih.gov/books/NBK557838/?utm_source=chatgpt.com
  67. Huxel, C., Raja, A., & Ollivierre-Lawrence, M. D. (2023b, May 22). Loop diuretics. StatPearls - NCBI Bookshelf. Retrieved October 30, 2025, from https://www.ncbi.nlm.nih.gov/books/NBK546656/
  68. Zannad, F., McMurray, J. J., Krum, H., Van Veldhuisen, D. J., Swedberg, K., Shi, H., Vincent, J., Pocock, S. J., & Pitt, B. (2010). Eplerenone in Patients with Systolic Heart Failure and Mild Symptoms. New England Journal of Medicine, 364(1), 11–21. https://doi.org/10.1056/nejmoa1009492
  69. Felker, G. M., Lee, K. L., Bull, D. A., Redfield, M. M., Stevenson, L. W., Goldsmith, S. R., LeWinter, M. M., Deswal, A., Rouleau, J. L., Ofili, E. O., Anstrom, K. J., Hernandez, A. F., McNulty, S. E., Velazquez, E. J., Kfoury, A. G., Chen, H. H., Givertz, M. M., Semigran, M. J., Bart, B. A., . . . O’Connor, C. M. (2011b). Diuretic strategies in patients with acute decompensated heart failure. New England Journal of Medicine, 364(9), 797–805. https://doi.org/10.1056/nejmoa1005419
  70. Pitt, B., Zannad, F., Remme, W. J., Cody, R., Castaigne, A., Perez, A., Palensky, J., & Wittes, J. (1999). The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure. New England Journal of Medicine, 341(10), 709–717. https://doi.org/10.1056/nejm199909023411001
  71. Felker, G. M., Lee, K. L., Bull, D. A., Redfield, M. M., Stevenson, L. W., Goldsmith, S. R., LeWinter, M. M., Deswal, A., Rouleau, J. L., Ofili, E. O., Anstrom, K. J., Hernandez, A. F., McNulty, S. E., Velazquez, E. J., Kfoury, A. G., Chen, H. H., Givertz, M. M., Semigran, M. J., Bart, B. A., . . . O’Connor, C. M. (2011). Diuretic Strategies in Patients with Acute Decompensated Heart Failure. New England Journal of Medicine, 364(9), 797–805. https://doi.org/10.1056/nejmoa1005419
  72. Pitt, B., Zannad, F., Remme, W. J., Cody, R., Castaigne, A., Perez, A., Palensky, J., & Wittes, J. (1999). The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure. New England Journal of Medicine, 341(10), 709–717. https://doi.org/10.1056/nejm199909023411001
  73. Felker, G. M., Lee, K. L., Bull, D. A., Redfield, M. M., Stevenson, L. W., Goldsmith, S. R., LeWinter, M. M., Deswal, A., Rouleau, J. L., Ofili, E. O., Anstrom, K. J., Hernandez, A. F., McNulty, S. E., Velazquez, E. J., Kfoury, A. G., Chen, H. H., Givertz, M. M., Semigran, M. J., Bart, B. A., . . . O’Connor, C. M. (2011). Diuretic Strategies in Patients with Acute Decompensated Heart Failure. New England Journal of Medicine, 364(9), 797–805. https://doi.org/10.1056/nejmoa1005419
  74. Zannad, F., McMurray, J. J., Krum, H., Van Veldhuisen, D. J., Swedberg, K., Shi, H., Vincent, J., Pocock, S. J., & Pitt, B. (2010). Eplerenone in Patients with Systolic Heart Failure and Mild Symptoms. New England Journal of Medicine, 364(1), 11–21. https://doi.org/10.1056/nejmoa1009492
  75. Huxel, C., Raja, A., & Ollivierre-Lawrence, M. D. (2023b, May 22). Loop diuretics. StatPearls - NCBI Bookshelf. Retrieved October 30, 2025, from https://www.ncbi.nlm.nih.gov/books/NBK546656/
  76. Zannad, F., McMurray, J. J., Krum, H., Van Veldhuisen, D. J., Swedberg, K., Shi, H., Vincent, J., Pocock, S. J., & Pitt, B. (2010). Eplerenone in Patients with Systolic Heart Failure and Mild Symptoms. New England Journal of Medicine, 364(1), 11–21. https://doi.org/10.1056/nejmoa1009492
  77. Huxel, C., Raja, A., & Ollivierre-Lawrence, M. D. (2023b, May 22). Loop diuretics. StatPearls - NCBI Bookshelf. Retrieved October 30, 2025, from https://www.ncbi.nlm.nih.gov/books/NBK546656/
  78. Zannad, F., McMurray, J. J., Krum, H., Van Veldhuisen, D. J., Swedberg, K., Shi, H., Vincent, J., Pocock, S. J., & Pitt, B. (2010). Eplerenone in Patients with Systolic Heart Failure and Mild Symptoms. New England Journal of Medicine, 364(1), 11–21. https://doi.org/10.1056/nejmoa1009492
  79. Pitt, B., Zannad, F., Remme, W. J., Cody, R., Castaigne, A., Perez, A., Palensky, J., & Wittes, J. (1999). The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure. New England Journal of Medicine, 341(10), 709–717. https://doi.org/10.1056/nejm199909023411001
  80. Pitt, B., Remme, W., Zannad, F., Neaton, J., Martinez, F., Roniker, B., Bittman, R., Hurley, S., Kleiman, J., & Gatlin, M. (2003). Eplerenone, a Selective Aldosterone Blocker, in Patients with Left Ventricular Dysfunction after Myocardial Infarction. New England Journal of Medicine, 348(14), 1309–1321. https://doi.org/10.1056/nejmoa030207
  81. Zannad, F., McMurray, J. J., Krum, H., Van Veldhuisen, D. J., Swedberg, K., Shi, H., Vincent, J., Pocock, S. J., & Pitt, B. (2010b). Eplerenone in Patients with Systolic Heart Failure and Mild Symptoms. New England Journal of Medicine, 364(1), 11–21. https://doi.org/10.1056/nejmoa1009492
  82. Pitt, B., Pfeffer, M. A., Assmann, S. F., Boineau, R., Anand, I. S., Claggett, B., Clausell, N., Desai, A. S., Diaz, R., Fleg, J. L., Gordeev, I., Harty, B., Heitner, J. F., Kenwood, C. T., Lewis, E. F., O’Meara, E., Probstfield, J. L., Shaburishvili, T., Shah, S. J., . . . McKinlay, S. M. (2014). Spironolactone for Heart Failure with Preserved Ejection Fraction. New England Journal of Medicine, 370(15), 1383–1392. https://doi.org/10.1056/nejmoa1313731
  83. Felker, G. M., Lee, K. L., Bull, D. A., Redfield, M. M., Stevenson, L. W., Goldsmith, S. R., LeWinter, M. M., Deswal, A., Rouleau, J. L., Ofili, E. O., Anstrom, K. J., Hernandez, A. F., McNulty, S. E., Velazquez, E. J., Kfoury, A. G., Chen, H. H., Givertz, M. M., Semigran, M. J., Bart, B. A., . . . O’Connor, C. M. (2011). Diuretic Strategies in Patients with Acute Decompensated Heart Failure. New England Journal of Medicine, 364(9), 797–805. https://doi.org/10.1056/nejmoa1005419
  84. Mentz, R. J., Anstrom, K. J., Eisenstein, E. L., Sapp, S., Greene, S. J., Morgan, S., Testani, J. M., Harrington, A. H., Sachdev, V., Ketema, F., Kim, D., Desvigne-Nickens, P., Pitt, B., Velazquez, E. J., Adams, K. F., Bhatt, K., DeWald, T., Axsom, K. M., Murthy, S., . . . Smart, F. (2023). Effect of Torsemide vs Furosemide After Discharge on All-Cause Mortality in Patients Hospitalized With Heart Failure. JAMA, 329(3), 214. https://doi.org/10.1001/jama.2022.23924
  85. Mullens, W., Dauw, J., Martens, P., Verbrugge, F. H., Nijst, P., Meekers, E., Tartaglia, K., Chenot, F., Moubayed, S., Dierckx, R., Blouard, P., Troisfontaines, P., Derthoo, D., Smolders, W., Bruckers, L., Droogne, W., Ter Maaten, J. M., Damman, K., Lassus, J., . . . Dupont, M. (2022). Acetazolamide in Acute Decompensated Heart Failure with Volume Overload. New England Journal of Medicine, 387(13), 1185–1195. https://doi.org/10.1056/nejmoa2203094
  86. Jhund, P. S., Talebi, A., Henderson, A. D., Claggett, B. L., Vaduganathan, M., Desai, A. S., Lam, C. S. P., Pitt, B., Senni, M., Shah, S. J., Voors, A. A., Zannad, F., Solomon, S. D., & McMurray, J. J. V. (2024). Mineralocorticoid receptor antagonists in heart failure: an individual patient level meta-analysis. The Lancet, 404(10458), 1119–1131. https://doi.org/10.1016/s0140-6736(24)01733-1
  87. Pitt, B., Zannad, F., Remme, W. J., Cody, R., Castaigne, A., Perez, A., Palensky, J., & Wittes, J. (1999). The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure. New England Journal of Medicine, 341(10), 709–717. https://doi.org/10.1056/nejm199909023411001
  88. Felker, G. M., Lee, K. L., Bull, D. A., Redfield, M. M., Stevenson, L. W., Goldsmith, S. R., LeWinter, M. M., Deswal, A., Rouleau, J. L., Ofili, E. O., Anstrom, K. J., Hernandez, A. F., McNulty, S. E., Velazquez, E. J., Kfoury, A. G., Chen, H. H., Givertz, M. M., Semigran, M. J., Bart, B. A., . . . O’Connor, C. M. (2011b). Diuretic Strategies in Patients with Acute Decompensated Heart Failure. New England Journal of Medicine, 364(9), 797–805. https://doi.org/10.1056/nejmoa1005419
  89. Mentz, R. J., Anstrom, K. J., Eisenstein, E. L., Sapp, S., Greene, S. J., Morgan, S., Testani, J. M., Harrington, A. H., Sachdev, V., Ketema, F., Kim, D., Desvigne-Nickens, P., Pitt, B., Velazquez, E. J., Adams, K. F., Bhatt, K., DeWald, T., Axsom, K. M., Murthy, S., . . . Smart, F. (2023b). Effect of Torsemide vs Furosemide After Discharge on All-Cause Mortality in Patients Hospitalized With Heart Failure. JAMA, 329(3), 214. https://doi.org/10.1001/jama.2022.23924
  90. Huxel, C., Raja, A., & Ollivierre-Lawrence, M. D. (2023b, May 22). Loop diuretics. StatPearls - NCBI Bookshelf. Retrieved October 30, 2025, from https://www.ncbi.nlm.nih.gov/books/NBK546656/
  91. Oh, S. W., & Han, S. Y. (2015). Loop diuretics in clinical practice. Electrolytes & Blood Pressure, 13(1), 17. https://doi.org/10.5049/ebp.2015.13.1.17
  92. Ding, D., Liu, H., Qi, W., Jiang, H., Li, Y., Wu, X., Sun, H., Gross, K., & Salvi, R. (2016). Ototoxic effects and mechanisms of loop diuretics. Journal of Otology, 11(4), 145–156. https://doi.org/10.1016/j.joto.2016.10.001
  93. Huxel, C., Raja, A., & Ollivierre-Lawrence, M. D. (2023b, May 22). Loop diuretics. StatPearls - NCBI Bookshelf. Retrieved October 30, 2025, from https://www.ncbi.nlm.nih.gov/books/NBK546656/
  94. Oh, S. W., & Han, S. Y. (2015b). Loop diuretics in clinical practice. Electrolytes & Blood Pressure, 13(1), 17. https://doi.org/10.5049/ebp.2015.13.1.17
  95. Oh, S. W., & Han, S. Y. (2015b). Loop diuretics in clinical practice. Electrolytes & Blood Pressure, 13(1), 17. https://doi.org/10.5049/ebp.2015.13.1.17
  96. Ding, D., Liu, H., Qi, W., Jiang, H., Li, Y., Wu, X., Sun, H., Gross, K., & Salvi, R. (2016). Ototoxic effects and mechanisms of loop diuretics. Journal of Otology, 11(4), 145–156. https://doi.org/10.1016/j.joto.2016.10.001
  97. Butler, J., Vijayakumar, S., & Pitt, B. (2018). Need to revisit heart failure treatment guidelines for hyperkalaemia management during the use of mineralocorticoid receptor antagonists. European Journal of Heart Failure, 20(9), 1247–1251. https://doi.org/10.1002/ejhf.1217
  98. Narayana, S., Veeregowda, S., Krishnamurthy, J., & Krishnaswamy, B. (2018). Spironolactone-induced unilateral gynecomastia. International Journal of Applied and Basic Medical Research, 8(1), 45. https://doi.org/10.4103/ijabmr.ijabmr_399_16
  99. Butler, J., Vijayakumar, S., & Pitt, B. (2018). Need to revisit heart failure treatment guidelines for hyperkalaemia management during the use of mineralocorticoid receptor antagonists. European Journal of Heart Failure, 20(9), 1247–1251. https://doi.org/10.1002/ejhf.1217
  100. Butler, J., Vijayakumar, S., & Pitt, B. (2018). Need to revisit heart failure treatment guidelines for hyperkalaemia management during the use of mineralocorticoid receptor antagonists. European Journal of Heart Failure, 20(9), 1247–1251. https://doi.org/10.1002/ejhf.1217
  101. Heidenreich, P. A., Bozkurt, B., Aguilar, D., Allen, L. A., Byun, J. J., Colvin, M. M., Deswal, A., Drazner, M. H., Dunlay, S. M., Evers, L. R., Fang, J. C., Fedson, S. E., Fonarow, G. C., Hayek, S. S., Hernandez, A. F., Khazanie, P., Kittleson, M. M., Lee, C. S., Link, M. S., . . . Yancy, C. W. (2022). 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation, 145(18). https://doi.org/10.1161/cir.0000000000001063
  102. Butler, J., Vijayakumar, S., & Pitt, B. (2018). Need to revisit heart failure treatment guidelines for hyperkalaemia management during the use of mineralocorticoid receptor antagonists. European Journal of Heart Failure, 20(9), 1247–1251. https://doi.org/10.1002/ejhf.1217
  103. Butler, J., Vijayakumar, S., & Pitt, B. (2018). Need to revisit heart failure treatment guidelines for hyperkalaemia management during the use of mineralocorticoid receptor antagonists. European Journal of Heart Failure, 20(9), 1247–1251. https://doi.org/10.1002/ejhf.1217
  104. Butler, J., Vijayakumar, S., & Pitt, B. (2018). Need to revisit heart failure treatment guidelines for hyperkalaemia management during the use of mineralocorticoid receptor antagonists. European Journal of Heart Failure, 20(9), 1247–1251. https://doi.org/10.1002/ejhf.1217
  105. Masi, S., Dalpiaz, H., Piludu, S., Piani, F., Fiorini, G., & Borghi, C. (2024). New strategies for the treatment of hyperkalemia. European Journal of Internal Medicine, 132, 18–26. https://doi.org/10.1016/j.ejim.2024.10.016
  106. Jentzer, J. C., DeWald, T. A., & Hernandez, A. F. (2010). Combination of loop diuretics with Thiazide-Type diuretics in heart failure. Journal of the American College of Cardiology, 56(19), 1527–1534. https://doi.org/10.1016/j.jacc.2010.06.034
  107. Steuber, T. D., Janzen, K. M., & Howard, M. L. (2020). A Systematic Review and Meta?Analysis of Metolazone compared to Chlorothiazide for Treatment of Acute Decompensated Heart Failure. Pharmacotherapy the Journal of Human Pharmacology and Drug Therapy, 40(9), 924–935. https://doi.org/10.1002/phar.2440
  108. Mullens, W., Dauw, J., Martens, P., Verbrugge, F. H., Nijst, P., Meekers, E., Tartaglia, K., Chenot, F., Moubayed, S., Dierckx, R., Blouard, P., Troisfontaines, P., Derthoo, D., Smolders, W., Bruckers, L., Droogne, W., Ter Maaten, J. M., Damman, K., Lassus, J., . . . Dupont, M. (2022b). Acetazolamide in Acute Decompensated Heart Failure with Volume Overload. New England Journal of Medicine, 387(13), 1185–1195. https://doi.org/10.1056/nejmoa2203094
  109. Oliva?Damaso, N., Nuñez, J., & Soler, M. J. (2023). Spot urinary sodium as a biomarker of diuretic response in acute heart failure. Journal of the American Heart Association, 12(17). https://doi.org/10.1161/jaha.123.030044
  110. Jentzer, J. C., DeWald, T. A., & Hernandez, A. F. (2010b). Combination of loop diuretics with Thiazide-Type diuretics in heart failure. Journal of the American College of Cardiology, 56(19), 1527–1534. https://doi.org/10.1016/j.jacc.2010.06.034
  111. Ayoti, R., Khan, Z., Mlawa, G., & Gupta, A. (2024). Assessing the Effectiveness and Safety of Combination Diuretic therapy in Heart Failure: A Systematic Review and Meta-Analysis. Cureus. https://doi.org/10.7759/cureus.72118
  112. Pitt, B., Filippatos, G., Agarwal, R., Anker, S. D., Bakris, G. L., Rossing, P., Joseph, A., Kolkhof, P., Nowack, C., Schloemer, P., & Ruilope, L. M. (2021). Cardiovascular Events with Finerenone in Kidney Disease and Type 2 Diabetes. New England Journal of Medicine, 385(24), 2252–2263. https://doi.org/10.1056/nejmoa2110956
  113. McMurray, J. J., Solomon, S. D., Inzucchi, S. E., Køber, L., Kosiborod, M. N., Martinez, F. A., Ponikowski, P., Sabatine, M. S., Anand, I. S., B?lohlávek, J., Böhm, M., Chiang, C., Chopra, V. K., De Boer, R. A., Desai, A. S., Diez, M., Drozdz, J., Dukát, A., Ge, J., . . . Langkilde, A. (2019). Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. New England Journal of Medicine, 381(21), 1995–2008. https://doi.org/10.1056/nejmoa1911303
  114. Bakris, G. L., Pitt, B., Weir, M. R., Freeman, M. W., Mayo, M. R., Garza, D., Stasiv, Y., Zawadzki, R., Berman, L., & Bushinsky, D. A. (2015). Effect of patiromer on serum potassium level in patients with hyperkalemia and diabetic kidney disease. JAMA, 314(2), 151. https://doi.org/10.1001/jama.2015.7446
  115. Oliva?Damaso, N., Nuñez, J., & Soler, M. J. (2023b). Spot urinary sodium as a biomarker of diuretic response in acute heart failure. Journal of the American Heart Association, 12(17). https://doi.org/10.1161/jaha.123.030044
  116. Mercier, J. A., Ferguson, T. W., & Tangri, N. (2022). A machine learning model to predict diuretic resistance. Kidney360, 4(1), 15–22. https://doi.org/10.34067/kid.0005562022

Reference

  1. Pitt B, Zannad F, Remme WJ, et al. (1999). The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure. New England Journal of Medicine, 341(10), 709-717.
  2. Felker GM, Leimberger JD, Califf RM, et al. (2007). Relation between dose of loop diuretics and outcomes in a heart-failure population: results of the ESCAPE trial. European Journal of Heart Failure, 9(10), 1064-1069.
  3. Felker GM, Ellison DH, Mullens W, Cox ZL, Testani JM. (2020). Diuretic Therapy for Patients With Heart Failure: JACC State-of-the-Art Review. Journal of the American College of Cardiology, 75(10), 1178-1195.
  4. Testani JM, et al. (2024). Diuretic Treatment in Heart Failure: A Practical Guide for Clinicians. Frontiers in Cardiovascular Medicine, 11, 11313642.
  5. Mullens W, et al. (2024). The Diuretic Optimisation Strategies Evaluation (DOSE) trial: Loop diuretic strategies in acute decompensated heart failure. European Heart Journal, 45(9), 10924023.
  6. Greene SJ, Velazquez EJ, Anstrom KJ, et al. (2023). Effect of Torsemide vs Furosemide after Discharge on All-Cause Mortality in Patients Hospitalized with Heart Failure: The TRANSFORM-HF Randomized Clinical Trial. JAMA, 329(3), 214-223.
  7. Vardeny O, et al. (2025). Finerenone, Serum Potassium, and Clinical Outcomes in Heart Failure (FINEARTS-HF). JAMA Cardiology.
  8. Georgianos PI, et al. (2024). Mineralocorticoid Receptor Antagonism in Heart Failure. Journal of the American College of Cardiology: Heart Failure.
  9. Jhund PS, et al. (2024). Mineralocorticoid receptor antagonists in heart failure: systematic review and meta-analysis. The Lancet.
  10. Jhund PS, et al. (2024). Mineralocorticoid receptor antagonists in heart failure: systematic review and meta-analysis. The Lancet.
  11. Pfeffer MA, Braunwald E. (2016). Treatment of Heart Failure With Preserved Ejection Fraction: Reflections on Its Treatment With an Aldosterone Antagonist. JAMA Cardiology, 1(1), 7-8.
  12. Yancy CW, et al. Edema formation in congestive heart failure and the underlying mechanisms. Front Cardiovasc Med. 2022.
  13. Triposkiadis F, et al. Sympathetic nervous system activation and heart failure. Curr Heart Fail Rep. 2020;17(3):191–200.
  14. Roh J, et al. Neurohormonal activation in heart failure with reduced ejection fraction. Heart Fail Rev. 2017;22(5):601–611.
  15. Rana I, et al. The renin–angiotensin–aldosterone system and myocardial remodeling. Front Physiol. 2023;14:1034170.
  16. Funder, J. W. (2010). Aldosterone and mineralocorticoid receptors in the cardiovascular system. Progress in Cardiovascular Diseases, 52(5), 393–400. https://doi.org/10.1016/j.pcad.2009.12.003
  17. Verbrugge FH, et al. Unveiling the systemic impact of congestion in heart failure. Card Fail Rev. 2024;10(1):e24.
  18. Schrier RW. Pathophysiology of sodium and water retention in heart failure. Cardiorenal Med. 2006;96(3–4):122–131.
  19. Francis GS, et al. Water and sodium regulation in heart failure. J Am Coll Cardiol. 2011;57(4):451–463.
  20. Ellison, D. H., & Felker, G. M. (2017). Diuretic treatment in heart failure. New England Journal of Medicine, 377(20), 1964–1975. https://doi.org/10.1056/nejmra1703100
  21. Schrier RW, et al. Complications of aggressive diuresis in decompensated heart failure. Cleve Clin J Med. 2006;73(Suppl 2):S2–S8.
  22. Gamba, G. (2023). From fish physiology to Human Disease: The discovery of the NCC, NKCC2, and the Cation-Coupled Chloride cotransporters. Kidney360, 5(1), 133–141. https://doi.org/10.34067/kid.0000000000000307
  23. Zacchia, M., Capolongo, G., Rinaldi, L., & Capasso, G. (2018). The importance of the thick ascending limb of Henle&rsquo;s loop in renal physiology and pathophysiology. International Journal of Nephrology and Renovascular Disease, Volume 11, 81–92. Https://doi.org/10.2147/ijnrd.s154000
  24. Huxel, C., Raja, A., & Ollivierre-Lawrence, M. D. (2023, May 22). Loop diuretics. StatPearls - NCBI Bookshelf. https://www.ncbi.nlm.nih.gov/books/NBK546656/?utm_source=chatgpt.com
  25. Yartsev, A. (n.d.). Furosemide. Deranged Physiology. https://derangedphysiology.com/main/cicm-primary-exam/renal-system/Chapter-022/furosemide?
  26. Shankar, S. S., & Brater, D. C. (2003). Loop diuretics: from the Na-K-2Cl transporter to clinical use. AJP Renal Physiology, 284(1), F11–F21. https://doi.org/10.1152/ajprenal.00119.2002
  27. Huxel, C., Raja, A., & Ollivierre-Lawrence, M. D. (2023, May 22). Loop diuretics. StatPearls - NCBI Bookshelf. https://www.ncbi.nlm.nih.gov/books/NBK546656/?utm_source=chatgpt.com
  28. Huxel, C., Raja, A., & Ollivierre-Lawrence, M. D. (2023b, May 22). Loop diuretics. StatPearls - NCBI Bookshelf. https://www.ncbi.nlm.nih.gov/books/NBK546656/?.com
  29. Buggey, J., Mentz, R. J., Pitt, B., Eisenstein, E. L., Anstrom, K. J., Velazquez, E. J., & O’Connor, C. M. (2015). A reappraisal of loop diuretic choice in heart failure patients. American Heart Journal, 169(3), 323–333. https://doi.org/10.1016/j.ahj.2014.12.009
  30. Wikipedia contributors. (2025, October 17). Bumetanide. Wikipedia. https://en.wikipedia.org/wiki/Bumetanide?
  31. Ellison, D. H. (2019). Clinical pharmacology in diuretic use. Clinical Journal of the American Society of Nephrology, 14(8), 1248–1257. https://doi.org/10.2215/cjn.09630818
  32. Practice Advisory [RETIRED]. (1996). Neurology, 47(3), 835–839. https://doi.org/10.1212/wnl.47.3.835
  33. Yartsev, A. (n.d.). Furosemide. Deranged Physiology. https://derangedphysiology.com/main/cicm-primary-exam/renal-system/Chapter-022/furosemide?
  34. Maskey, D., Pineda, J. G., & Ortiz, P. A. (2024). Update on NKCC2 regulation in the thick ascending limb (TAL) by membrane trafficking, phosphorylation, and protein-protein interactions. Frontiers in Physiology, 15. https://doi.org/10.3389/fphys.2024.1508806
  35. Rao, V. S., Planavsky, N., Hanberg, J. S., Ahmad, T., Brisco-Bacik, M. A., Wilson, F. P., Jacoby, D., Chen, M., Tang, W. W., Cherney, D. Z., Ellison, D. H., & Testani, J. M. (2017). Compensatory distal reabsorption drives diuretic resistance in human heart failure. Journal of the American Society of Nephrology, 28(11), 3414–3424. https://doi.org/10.1681/asn.2016111178
  36. Cox, Z. L., Rao, V. S., & Testani, J. M. (2022). Classic and novel mechanisms of diuretic resistance in cardiorenal syndrome. Kidney360, 3(5), 954–967. https://doi.org/10.34067/kid.0006372021
  37. Felker, G. M., Lee, K. L., Bull, D. A., Redfield, M. M., Stevenson, L. W., Goldsmith, S. R., LeWinter, M. M., Deswal, A., Rouleau, J. L., Ofili, E. O., Anstrom, K. J., Hernandez, A. F., McNulty, S. E., Velazquez, E. J., Kfoury, A. G., Chen, H. H., Givertz, M. M., Semigran, M. J., Bart, B. A., . . . O’Connor, C. M. (2011c). Diuretic Strategies in Patients with Acute Decompensated Heart Failure. New England Journal of Medicine, 364(9), 797–805. https://doi.org/10.1056/nejmoa1005419
  38. Mentz, R. J., Anstrom, K. J., Eisenstein, E. L., Sapp, S., Greene, S. J., Morgan, S., Testani, J. M., Harrington, A. H., Sachdev, V., Ketema, F., Kim, D., Desvigne-Nickens, P., Pitt, B., Velazquez, E. J., Adams, K. F., Bhatt, K., DeWald, T., Axsom, K. M., Murthy, S., . . . Smart, F. (2023c). Effect of Torsemide vs Furosemide After Discharge on All-Cause Mortality in Patients Hospitalized With Heart Failure. JAMA, 329(3), 214. https://doi.org/10.1001/jama.2022.23924
  39. Sica, D. A. (2015). Mineralocorticoid receptor antagonists for treatment of hypertension and heart failure. Methodist DeBakey Cardiovascular Journal, 11(4), 235. https://doi.org/10.14797/mdcj-11-4-235
  40. Sica, D. A. (2015). Mineralocorticoid receptor antagonists for treatment of hypertension and heart failure. Methodist DeBakey Cardiovascular Journal, 11(4), 235. https://doi.org/10.14797/mdcj-11-4-235
  41. Almajid, A. N., Patel, P., & Cassagnol, M. (2024, February 28). Amiloride. StatPearls - NCBI Bookshelf. https://www.ncbi.nlm.nih.gov/books/NBK542303/?
  42. ALDACTONE® (spironolactone) Clinical Pharmacology | Pfizer Medical - US. (n.d.). https://www.pfizermedical.com/aldactone/clinical-pharmacology?
  43. Takeda, Y. (2009). Effects of eplerenone, a selective mineralocorticoid receptor antagonist, on clinical and experimental salt-sensitive hypertension. Hypertension Research, 32(5), 321–324. https://doi.org/10.1038/hr.2009.29
  44. Pitt, B., Filippatos, G., Agarwal, R., Anker, S. D., Bakris, G. L., Rossing, P., Joseph, A., Kolkhof, P., Nowack, C., Schloemer, P., & Ruilope, L. M. (2021b). Cardiovascular Events with Finerenone in Kidney Disease and Type 2 Diabetes. New England Journal of Medicine, 385(24), 2252–2263. https://doi.org/10.1056/nejmoa2110956
  45. ALDACTONE® (spironolactone) Clinical Pharmacology Patient information | Pfizer Medical - US. (n.d.). https://www.pfizermedical.com/patient/aldactone/clinical-pharmacology?utm_source=chatgpt.com
  46. Pitt, B., Zannad, F., Remme, W. J., Cody, R., Castaigne, A., Perez, A., Palensky, J., & Wittes, J. (1999). The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure. New England Journal of Medicine, 341(10), 709–717. https://doi.org/10.1056/nejm199909023411001
  47. Pitt, B., Remme, W., Zannad, F., Neaton, J., Martinez, F., Roniker, B., Bittman, R., Hurley, S., Kleiman, J., & Gatlin, M. (2003). Eplerenone, a Selective Aldosterone Blocker, in Patients with Left Ventricular Dysfunction after Myocardial Infarction. New England Journal of Medicine, 348(14), 1309–1321. https://doi.org/10.1056/nejmoa030207
  48. Pitt, B., Pfeffer, M. A., Assmann, S. F., Boineau, R., Anand, I. S., Claggett, B., Clausell, N., Desai, A. S., Diaz, R., Fleg, J. L., Gordeev, I., Harty, B., Heitner, J. F., Kenwood, C. T., Lewis, E. F., O’Meara, E., Probstfield, J. L., Shaburishvili, T., Shah, S. J., . . . McKinlay, S. M. (2014). Spironolactone for Heart Failure with Preserved Ejection Fraction. New England Journal of Medicine, 370(15), 1383–1392. https://doi.org/10.1056/nejmoa1313731
  49. Pitt, B., Filippatos, G., Agarwal, R., Anker, S. D., Bakris, G. L., Rossing, P., Joseph, A., Kolkhof, P., Nowack, C., Schloemer, P., & Ruilope, L. M. (2021). Cardiovascular Events with Finerenone in Kidney Disease and Type 2 Diabetes. New England Journal of Medicine, 385(24), 2252–2263. https://doi.org/10.1056/nejmoa2110956
  50. Almajid, A. N., Patel, P., & Cassagnol, M. (2024, February 28). Amiloride. StatPearls - NCBI Bookshelf. https://www.ncbi.nlm.nih.gov/books/NBK542303/?
  51. Patiromer for the Management of Hyperkalemia in Subjects receiving RAASI for HFREF - American College of Cardiology. (2022, April 2). American College of Cardiology. https://www.acc.org/Latest-in-Cardiology/Clinical-Trials/2022/04/02/15/56/DIAMOND
  52. Anker, S. D., Kosiborod, M., Zannad, F., Piña, I. L., McCullough, P. A., Filippatos, G., Van Der Meer, P., Ponikowski, P., Rasmussen, H. S., Lavin, P. T., Singh, B., Yang, A., & Deedwania, P. (2015). Maintenance of serum potassium with sodium zirconium cyclosilicate (ZS?9) in heart failure patients: results from a phase 3 randomized, double?blind, placebo?controlled trial. European Journal of Heart Failure, 17(10), 1050–1056. https://doi.org/10.1002/ejhf.300
  53. Butler, J., Anker, S. D., Lund, L. H., Coats, A. J. S., Filippatos, G., Siddiqi, T. J., Friede, T., Fabien, V., Kosiborod, M., Metra, M., Piña, I. L., Pinto, F., Rossignol, P., Van Der Meer, P., Bahit, C., Belohlavek, J., Böhm, M., Brugts, J. J., Cleland, J. G. F., . . . Pitt, B. (2022). Patiromer for the management of hyperkalemia in heart failure with reduced ejection fraction: the DIAMOND trial. European Heart Journal, 43(41), 4362–4373. https://doi.org/10.1093/eurheartj/ehac401
  54. Sica, D. A. (2015). Mineralocorticoid receptor antagonists for treatment of hypertension and heart failure. Methodist DeBakey Cardiovascular Journal, 11(4), 235. https://doi.org/10.14797/mdcj-11-4-235
  55. Brown, N. J. (2003). Eplerenone. Circulation, 107(19), 2512–2518. https://doi.org/10.1161/01.cir.0000071081.35693.9a
  56. ALDACTONE® (spironolactone) Clinical Pharmacology Patient information | Pfizer Medical - US. (n.d.). https://www.pfizermedical.com/patient/aldactone/clinical-pharmacology?utm_source=chatgpt.com
  57. Felker, G. M., Lee, K. L., Bull, D. A., Redfield, M. M., Stevenson, L. W., Goldsmith, S. R., LeWinter, M. M., Deswal, A., Rouleau, J. L., Ofili, E. O., Anstrom, K. J., Hernandez, A. F., McNulty, S. E., Velazquez, E. J., Kfoury, A. G., Chen, H. H., Givertz, M. M., Semigran, M. J., Bart, B. A., . . . O’Connor, C. M. (2011). Diuretic Strategies in Patients with Acute Decompensated Heart Failure. New England Journal of Medicine, 364(9), 797–805. https://doi.org/10.1056/nejmoa1005419
  58. Zannad, F., McMurray, J. J., Krum, H., Van Veldhuisen, D. J., Swedberg, K., Shi, H., Vincent, J., Pocock, S. J., & Pitt, B. (2010). Eplerenone in Patients with Systolic Heart Failure and Mild Symptoms. New England Journal of Medicine, 364(1), 11–21. https://doi.org/10.1056/nejmoa1009492
  59. Huxel, C., Raja, A., & Ollivierre-Lawrence, M. D. (2023, May 22). Loop diuretics. StatPearls - NCBI Bookshelf. https://www.ncbi.nlm.nih.gov/books/NBK546656/
  60. Arumugham, V. B., & Shahin, M. H. (2023, May 29). Therapeutic uses of diuretic agents. StatPearls - NCBI Bookshelf. https://www.ncbi.nlm.nih.gov/books/NBK557838/
  61. Felker, G. M., Lee, K. L., Bull, D. A., Redfield, M. M., Stevenson, L. W., Goldsmith, S. R., LeWinter, M. M., Deswal, A., Rouleau, J. L., Ofili, E. O., Anstrom, K. J., Hernandez, A. F., McNulty, S. E., Velazquez, E. J., Kfoury, A. G., Chen, H. H., Givertz, M. M., Semigran, M. J., Bart, B. A., . . . O’Connor, C. M. (2011). Diuretic Strategies in Patients with Acute Decompensated Heart Failure. New England Journal of Medicine, 364(9), 797–805. https://doi.org/10.1056/nejmoa1005419
  62. Arumugham, V. B., & Shahin, M. H. (2023b, May 29). Therapeutic uses of diuretic agents. StatPearls - NCBI Bookshelf. https://www.ncbi.nlm.nih.gov/books/NBK557838/
  63. Huxel, C., Raja, A., & Ollivierre-Lawrence, M. D. (2023, May 22). Loop diuretics. StatPearls - NCBI Bookshelf. Retrieved October 30, 2025, from https://www.ncbi.nlm.nih.gov/books/NBK546656/
  64. Zannad, F., McMurray, J. J., Krum, H., Van Veldhuisen, D. J., Swedberg, K., Shi, H., Vincent, J., Pocock, S. J., & Pitt, B. (2010). Eplerenone in Patients with Systolic Heart Failure and Mild Symptoms. New England Journal of Medicine, 364(1), 11–21. https://doi.org/10.1056/nejmoa1009492
  65. Huxel, C., Raja, A., & Ollivierre-Lawrence, M. D. (2023b, May 22). Loop diuretics. StatPearls - NCBI Bookshelf. Retrieved October 30, 2025, from https://www.ncbi.nlm.nih.gov/books/NBK546656/
  66. Arumugham, V. B., & Shahin, M. H. (2023c, May 29). Therapeutic uses of diuretic agents. StatPearls - NCBI Bookshelf. https://www.ncbi.nlm.nih.gov/books/NBK557838/?utm_source=chatgpt.com
  67. Huxel, C., Raja, A., & Ollivierre-Lawrence, M. D. (2023b, May 22). Loop diuretics. StatPearls - NCBI Bookshelf. Retrieved October 30, 2025, from https://www.ncbi.nlm.nih.gov/books/NBK546656/
  68. Zannad, F., McMurray, J. J., Krum, H., Van Veldhuisen, D. J., Swedberg, K., Shi, H., Vincent, J., Pocock, S. J., & Pitt, B. (2010). Eplerenone in Patients with Systolic Heart Failure and Mild Symptoms. New England Journal of Medicine, 364(1), 11–21. https://doi.org/10.1056/nejmoa1009492
  69. Felker, G. M., Lee, K. L., Bull, D. A., Redfield, M. M., Stevenson, L. W., Goldsmith, S. R., LeWinter, M. M., Deswal, A., Rouleau, J. L., Ofili, E. O., Anstrom, K. J., Hernandez, A. F., McNulty, S. E., Velazquez, E. J., Kfoury, A. G., Chen, H. H., Givertz, M. M., Semigran, M. J., Bart, B. A., . . . O’Connor, C. M. (2011b). Diuretic strategies in patients with acute decompensated heart failure. New England Journal of Medicine, 364(9), 797–805. https://doi.org/10.1056/nejmoa1005419
  70. Pitt, B., Zannad, F., Remme, W. J., Cody, R., Castaigne, A., Perez, A., Palensky, J., & Wittes, J. (1999). The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure. New England Journal of Medicine, 341(10), 709–717. https://doi.org/10.1056/nejm199909023411001
  71. Felker, G. M., Lee, K. L., Bull, D. A., Redfield, M. M., Stevenson, L. W., Goldsmith, S. R., LeWinter, M. M., Deswal, A., Rouleau, J. L., Ofili, E. O., Anstrom, K. J., Hernandez, A. F., McNulty, S. E., Velazquez, E. J., Kfoury, A. G., Chen, H. H., Givertz, M. M., Semigran, M. J., Bart, B. A., . . . O’Connor, C. M. (2011). Diuretic Strategies in Patients with Acute Decompensated Heart Failure. New England Journal of Medicine, 364(9), 797–805. https://doi.org/10.1056/nejmoa1005419
  72. Pitt, B., Zannad, F., Remme, W. J., Cody, R., Castaigne, A., Perez, A., Palensky, J., & Wittes, J. (1999). The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure. New England Journal of Medicine, 341(10), 709–717. https://doi.org/10.1056/nejm199909023411001
  73. Felker, G. M., Lee, K. L., Bull, D. A., Redfield, M. M., Stevenson, L. W., Goldsmith, S. R., LeWinter, M. M., Deswal, A., Rouleau, J. L., Ofili, E. O., Anstrom, K. J., Hernandez, A. F., McNulty, S. E., Velazquez, E. J., Kfoury, A. G., Chen, H. H., Givertz, M. M., Semigran, M. J., Bart, B. A., . . . O’Connor, C. M. (2011). Diuretic Strategies in Patients with Acute Decompensated Heart Failure. New England Journal of Medicine, 364(9), 797–805. https://doi.org/10.1056/nejmoa1005419
  74. Zannad, F., McMurray, J. J., Krum, H., Van Veldhuisen, D. J., Swedberg, K., Shi, H., Vincent, J., Pocock, S. J., & Pitt, B. (2010). Eplerenone in Patients with Systolic Heart Failure and Mild Symptoms. New England Journal of Medicine, 364(1), 11–21. https://doi.org/10.1056/nejmoa1009492
  75. Huxel, C., Raja, A., & Ollivierre-Lawrence, M. D. (2023b, May 22). Loop diuretics. StatPearls - NCBI Bookshelf. Retrieved October 30, 2025, from https://www.ncbi.nlm.nih.gov/books/NBK546656/
  76. Zannad, F., McMurray, J. J., Krum, H., Van Veldhuisen, D. J., Swedberg, K., Shi, H., Vincent, J., Pocock, S. J., & Pitt, B. (2010). Eplerenone in Patients with Systolic Heart Failure and Mild Symptoms. New England Journal of Medicine, 364(1), 11–21. https://doi.org/10.1056/nejmoa1009492
  77. Huxel, C., Raja, A., & Ollivierre-Lawrence, M. D. (2023b, May 22). Loop diuretics. StatPearls - NCBI Bookshelf. Retrieved October 30, 2025, from https://www.ncbi.nlm.nih.gov/books/NBK546656/
  78. Zannad, F., McMurray, J. J., Krum, H., Van Veldhuisen, D. J., Swedberg, K., Shi, H., Vincent, J., Pocock, S. J., & Pitt, B. (2010). Eplerenone in Patients with Systolic Heart Failure and Mild Symptoms. New England Journal of Medicine, 364(1), 11–21. https://doi.org/10.1056/nejmoa1009492
  79. Pitt, B., Zannad, F., Remme, W. J., Cody, R., Castaigne, A., Perez, A., Palensky, J., & Wittes, J. (1999). The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure. New England Journal of Medicine, 341(10), 709–717. https://doi.org/10.1056/nejm199909023411001
  80. Pitt, B., Remme, W., Zannad, F., Neaton, J., Martinez, F., Roniker, B., Bittman, R., Hurley, S., Kleiman, J., & Gatlin, M. (2003). Eplerenone, a Selective Aldosterone Blocker, in Patients with Left Ventricular Dysfunction after Myocardial Infarction. New England Journal of Medicine, 348(14), 1309–1321. https://doi.org/10.1056/nejmoa030207
  81. Zannad, F., McMurray, J. J., Krum, H., Van Veldhuisen, D. J., Swedberg, K., Shi, H., Vincent, J., Pocock, S. J., & Pitt, B. (2010b). Eplerenone in Patients with Systolic Heart Failure and Mild Symptoms. New England Journal of Medicine, 364(1), 11–21. https://doi.org/10.1056/nejmoa1009492
  82. Pitt, B., Pfeffer, M. A., Assmann, S. F., Boineau, R., Anand, I. S., Claggett, B., Clausell, N., Desai, A. S., Diaz, R., Fleg, J. L., Gordeev, I., Harty, B., Heitner, J. F., Kenwood, C. T., Lewis, E. F., O’Meara, E., Probstfield, J. L., Shaburishvili, T., Shah, S. J., . . . McKinlay, S. M. (2014). Spironolactone for Heart Failure with Preserved Ejection Fraction. New England Journal of Medicine, 370(15), 1383–1392. https://doi.org/10.1056/nejmoa1313731
  83. Felker, G. M., Lee, K. L., Bull, D. A., Redfield, M. M., Stevenson, L. W., Goldsmith, S. R., LeWinter, M. M., Deswal, A., Rouleau, J. L., Ofili, E. O., Anstrom, K. J., Hernandez, A. F., McNulty, S. E., Velazquez, E. J., Kfoury, A. G., Chen, H. H., Givertz, M. M., Semigran, M. J., Bart, B. A., . . . O’Connor, C. M. (2011). Diuretic Strategies in Patients with Acute Decompensated Heart Failure. New England Journal of Medicine, 364(9), 797–805. https://doi.org/10.1056/nejmoa1005419
  84. Mentz, R. J., Anstrom, K. J., Eisenstein, E. L., Sapp, S., Greene, S. J., Morgan, S., Testani, J. M., Harrington, A. H., Sachdev, V., Ketema, F., Kim, D., Desvigne-Nickens, P., Pitt, B., Velazquez, E. J., Adams, K. F., Bhatt, K., DeWald, T., Axsom, K. M., Murthy, S., . . . Smart, F. (2023). Effect of Torsemide vs Furosemide After Discharge on All-Cause Mortality in Patients Hospitalized With Heart Failure. JAMA, 329(3), 214. https://doi.org/10.1001/jama.2022.23924
  85. Mullens, W., Dauw, J., Martens, P., Verbrugge, F. H., Nijst, P., Meekers, E., Tartaglia, K., Chenot, F., Moubayed, S., Dierckx, R., Blouard, P., Troisfontaines, P., Derthoo, D., Smolders, W., Bruckers, L., Droogne, W., Ter Maaten, J. M., Damman, K., Lassus, J., . . . Dupont, M. (2022). Acetazolamide in Acute Decompensated Heart Failure with Volume Overload. New England Journal of Medicine, 387(13), 1185–1195. https://doi.org/10.1056/nejmoa2203094
  86. Jhund, P. S., Talebi, A., Henderson, A. D., Claggett, B. L., Vaduganathan, M., Desai, A. S., Lam, C. S. P., Pitt, B., Senni, M., Shah, S. J., Voors, A. A., Zannad, F., Solomon, S. D., & McMurray, J. J. V. (2024). Mineralocorticoid receptor antagonists in heart failure: an individual patient level meta-analysis. The Lancet, 404(10458), 1119–1131. https://doi.org/10.1016/s0140-6736(24)01733-1
  87. Pitt, B., Zannad, F., Remme, W. J., Cody, R., Castaigne, A., Perez, A., Palensky, J., & Wittes, J. (1999). The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure. New England Journal of Medicine, 341(10), 709–717. https://doi.org/10.1056/nejm199909023411001
  88. Felker, G. M., Lee, K. L., Bull, D. A., Redfield, M. M., Stevenson, L. W., Goldsmith, S. R., LeWinter, M. M., Deswal, A., Rouleau, J. L., Ofili, E. O., Anstrom, K. J., Hernandez, A. F., McNulty, S. E., Velazquez, E. J., Kfoury, A. G., Chen, H. H., Givertz, M. M., Semigran, M. J., Bart, B. A., . . . O’Connor, C. M. (2011b). Diuretic Strategies in Patients with Acute Decompensated Heart Failure. New England Journal of Medicine, 364(9), 797–805. https://doi.org/10.1056/nejmoa1005419
  89. Mentz, R. J., Anstrom, K. J., Eisenstein, E. L., Sapp, S., Greene, S. J., Morgan, S., Testani, J. M., Harrington, A. H., Sachdev, V., Ketema, F., Kim, D., Desvigne-Nickens, P., Pitt, B., Velazquez, E. J., Adams, K. F., Bhatt, K., DeWald, T., Axsom, K. M., Murthy, S., . . . Smart, F. (2023b). Effect of Torsemide vs Furosemide After Discharge on All-Cause Mortality in Patients Hospitalized With Heart Failure. JAMA, 329(3), 214. https://doi.org/10.1001/jama.2022.23924
  90. Huxel, C., Raja, A., & Ollivierre-Lawrence, M. D. (2023b, May 22). Loop diuretics. StatPearls - NCBI Bookshelf. Retrieved October 30, 2025, from https://www.ncbi.nlm.nih.gov/books/NBK546656/
  91. Oh, S. W., & Han, S. Y. (2015). Loop diuretics in clinical practice. Electrolytes & Blood Pressure, 13(1), 17. https://doi.org/10.5049/ebp.2015.13.1.17
  92. Ding, D., Liu, H., Qi, W., Jiang, H., Li, Y., Wu, X., Sun, H., Gross, K., & Salvi, R. (2016). Ototoxic effects and mechanisms of loop diuretics. Journal of Otology, 11(4), 145–156. https://doi.org/10.1016/j.joto.2016.10.001
  93. Huxel, C., Raja, A., & Ollivierre-Lawrence, M. D. (2023b, May 22). Loop diuretics. StatPearls - NCBI Bookshelf. Retrieved October 30, 2025, from https://www.ncbi.nlm.nih.gov/books/NBK546656/
  94. Oh, S. W., & Han, S. Y. (2015b). Loop diuretics in clinical practice. Electrolytes & Blood Pressure, 13(1), 17. https://doi.org/10.5049/ebp.2015.13.1.17
  95. Oh, S. W., & Han, S. Y. (2015b). Loop diuretics in clinical practice. Electrolytes & Blood Pressure, 13(1), 17. https://doi.org/10.5049/ebp.2015.13.1.17
  96. Ding, D., Liu, H., Qi, W., Jiang, H., Li, Y., Wu, X., Sun, H., Gross, K., & Salvi, R. (2016). Ototoxic effects and mechanisms of loop diuretics. Journal of Otology, 11(4), 145–156. https://doi.org/10.1016/j.joto.2016.10.001
  97. Butler, J., Vijayakumar, S., & Pitt, B. (2018). Need to revisit heart failure treatment guidelines for hyperkalaemia management during the use of mineralocorticoid receptor antagonists. European Journal of Heart Failure, 20(9), 1247–1251. https://doi.org/10.1002/ejhf.1217
  98. Narayana, S., Veeregowda, S., Krishnamurthy, J., & Krishnaswamy, B. (2018). Spironolactone-induced unilateral gynecomastia. International Journal of Applied and Basic Medical Research, 8(1), 45. https://doi.org/10.4103/ijabmr.ijabmr_399_16
  99. Butler, J., Vijayakumar, S., & Pitt, B. (2018). Need to revisit heart failure treatment guidelines for hyperkalaemia management during the use of mineralocorticoid receptor antagonists. European Journal of Heart Failure, 20(9), 1247–1251. https://doi.org/10.1002/ejhf.1217
  100. Butler, J., Vijayakumar, S., & Pitt, B. (2018). Need to revisit heart failure treatment guidelines for hyperkalaemia management during the use of mineralocorticoid receptor antagonists. European Journal of Heart Failure, 20(9), 1247–1251. https://doi.org/10.1002/ejhf.1217
  101. Heidenreich, P. A., Bozkurt, B., Aguilar, D., Allen, L. A., Byun, J. J., Colvin, M. M., Deswal, A., Drazner, M. H., Dunlay, S. M., Evers, L. R., Fang, J. C., Fedson, S. E., Fonarow, G. C., Hayek, S. S., Hernandez, A. F., Khazanie, P., Kittleson, M. M., Lee, C. S., Link, M. S., . . . Yancy, C. W. (2022). 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation, 145(18). https://doi.org/10.1161/cir.0000000000001063
  102. Butler, J., Vijayakumar, S., & Pitt, B. (2018). Need to revisit heart failure treatment guidelines for hyperkalaemia management during the use of mineralocorticoid receptor antagonists. European Journal of Heart Failure, 20(9), 1247–1251. https://doi.org/10.1002/ejhf.1217
  103. Butler, J., Vijayakumar, S., & Pitt, B. (2018). Need to revisit heart failure treatment guidelines for hyperkalaemia management during the use of mineralocorticoid receptor antagonists. European Journal of Heart Failure, 20(9), 1247–1251. https://doi.org/10.1002/ejhf.1217
  104. Butler, J., Vijayakumar, S., & Pitt, B. (2018). Need to revisit heart failure treatment guidelines for hyperkalaemia management during the use of mineralocorticoid receptor antagonists. European Journal of Heart Failure, 20(9), 1247–1251. https://doi.org/10.1002/ejhf.1217
  105. Masi, S., Dalpiaz, H., Piludu, S., Piani, F., Fiorini, G., & Borghi, C. (2024). New strategies for the treatment of hyperkalemia. European Journal of Internal Medicine, 132, 18–26. https://doi.org/10.1016/j.ejim.2024.10.016
  106. Jentzer, J. C., DeWald, T. A., & Hernandez, A. F. (2010). Combination of loop diuretics with Thiazide-Type diuretics in heart failure. Journal of the American College of Cardiology, 56(19), 1527–1534. https://doi.org/10.1016/j.jacc.2010.06.034
  107. Steuber, T. D., Janzen, K. M., & Howard, M. L. (2020). A Systematic Review and Meta?Analysis of Metolazone compared to Chlorothiazide for Treatment of Acute Decompensated Heart Failure. Pharmacotherapy the Journal of Human Pharmacology and Drug Therapy, 40(9), 924–935. https://doi.org/10.1002/phar.2440
  108. Mullens, W., Dauw, J., Martens, P., Verbrugge, F. H., Nijst, P., Meekers, E., Tartaglia, K., Chenot, F., Moubayed, S., Dierckx, R., Blouard, P., Troisfontaines, P., Derthoo, D., Smolders, W., Bruckers, L., Droogne, W., Ter Maaten, J. M., Damman, K., Lassus, J., . . . Dupont, M. (2022b). Acetazolamide in Acute Decompensated Heart Failure with Volume Overload. New England Journal of Medicine, 387(13), 1185–1195. https://doi.org/10.1056/nejmoa2203094
  109. Oliva?Damaso, N., Nuñez, J., & Soler, M. J. (2023). Spot urinary sodium as a biomarker of diuretic response in acute heart failure. Journal of the American Heart Association, 12(17). https://doi.org/10.1161/jaha.123.030044
  110. Jentzer, J. C., DeWald, T. A., & Hernandez, A. F. (2010b). Combination of loop diuretics with Thiazide-Type diuretics in heart failure. Journal of the American College of Cardiology, 56(19), 1527–1534. https://doi.org/10.1016/j.jacc.2010.06.034
  111. Ayoti, R., Khan, Z., Mlawa, G., & Gupta, A. (2024). Assessing the Effectiveness and Safety of Combination Diuretic therapy in Heart Failure: A Systematic Review and Meta-Analysis. Cureus. https://doi.org/10.7759/cureus.72118
  112. Pitt, B., Filippatos, G., Agarwal, R., Anker, S. D., Bakris, G. L., Rossing, P., Joseph, A., Kolkhof, P., Nowack, C., Schloemer, P., & Ruilope, L. M. (2021). Cardiovascular Events with Finerenone in Kidney Disease and Type 2 Diabetes. New England Journal of Medicine, 385(24), 2252–2263. https://doi.org/10.1056/nejmoa2110956
  113. McMurray, J. J., Solomon, S. D., Inzucchi, S. E., Køber, L., Kosiborod, M. N., Martinez, F. A., Ponikowski, P., Sabatine, M. S., Anand, I. S., B?lohlávek, J., Böhm, M., Chiang, C., Chopra, V. K., De Boer, R. A., Desai, A. S., Diez, M., Drozdz, J., Dukát, A., Ge, J., . . . Langkilde, A. (2019). Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. New England Journal of Medicine, 381(21), 1995–2008. https://doi.org/10.1056/nejmoa1911303
  114. Bakris, G. L., Pitt, B., Weir, M. R., Freeman, M. W., Mayo, M. R., Garza, D., Stasiv, Y., Zawadzki, R., Berman, L., & Bushinsky, D. A. (2015). Effect of patiromer on serum potassium level in patients with hyperkalemia and diabetic kidney disease. JAMA, 314(2), 151. https://doi.org/10.1001/jama.2015.7446
  115. Oliva?Damaso, N., Nuñez, J., & Soler, M. J. (2023b). Spot urinary sodium as a biomarker of diuretic response in acute heart failure. Journal of the American Heart Association, 12(17). https://doi.org/10.1161/jaha.123.030044
  116. Mercier, J. A., Ferguson, T. W., & Tangri, N. (2022). A machine learning model to predict diuretic resistance. Kidney360, 4(1), 15–22. https://doi.org/10.34067/kid.0005562022

Photo
Onkar Ramanshetti
Corresponding author

Department of Pharmacy Practice, Shivlingeshwar College of Pharmacy, Almala, Latur.

Photo
Divya Chordiya
Co-author

Department of Pharmacy Practice, Shivlingeshwar College of Pharmacy, Almala, Latur.

Photo
Komal Giri
Co-author

Department of Pharmacy Practice, Shivlingeshwar College of Pharmacy, Almala, Latur.

Photo
Yogesh Sawant
Co-author

Department of Pharmacy Practice, Shivlingeshwar College of Pharmacy, Almala, Latur.

Photo
Akshay Bhambre
Co-author

Department of Pharmacy Practice, Shivlingeshwar College of Pharmacy, Almala, Latur.

Onkar Ramanshetti, Divya Chordiya, Komal Giri, Yogesh Sawant, Akshay Bhambre, Comparative Evaluation of Loop and Potassium-Sparing Diuretics in Heart Failure: Mechanisms, Clinical Roles, and Outcomes, Int. J. of Pharm. Sci., 2026, Vol 4, Issue 1, 192-215. https://doi.org/10.5281/zenodo.18137855

More related articles
A Review on Formulation and Evaluation of Efferves...
Deshmukh Komal, Narsale Somanath, Salve Bhumika, Chavan Rutuja, ...
Sustainable Shielding: Comparative Analysis of Edi...
Kashish Mulani, Saniya Mulla, Nikita Sawant, Kalyani Gardi, Bhara...
Film Forming Gels: A Review ...
Pradnya K Gangurde, Kajal A Choursiya, Saba Shaikh, Shardha Kanda...
View more
Regenerative Medicine...
Baswa Akhila, Balaga Usha Devi , Gandham Jasmine , S. Chandana Priya, ...
A Review On Diabetes Mellitus: Complications, Management And Treatment...
Manasi Patil, Abraul Haque, Tanmaya Patil, ...
Review On Formulation and Evaluation of Oral Medicated Jellies Containing Acyclo...
Vrushali Pawar , Mitesh Sonawane , ...
View more
Download PDF
Related Articles
The Factors, Identification and Management of Nail Disorders...
Sanika Ladhaikar, Sharvari Pande, Gagan Shendre, Dhammadip Nandgaye, ...
Formulation and evaluation of antianxiolytic aroma spray from asamantara and lem...
Madhavi Kankute, Tejaswini Dhawale, ...
Formulation and Evaluation of Herbal Face Scrub Using Pomegranate Peel ...
Sakshi Tayade, Vaishnavi Gawande, Sunil Bhagat, Swati Deshmukh, ...
Rapid RP-HPLC Method For the Dual Drug Analysis of Azelnidipine and Chlorthalido...
Reeba K. R., Prasanth S. S., ...
A Review on Formulation and Evaluation of Effervescent Tablet ...
Deshmukh Komal, Narsale Somanath, Salve Bhumika, Chavan Rutuja, ...
More related articles
A Review on Formulation and Evaluation of Effervescent Tablet ...
Deshmukh Komal, Narsale Somanath, Salve Bhumika, Chavan Rutuja, ...
Sustainable Shielding: Comparative Analysis of Edible Thin Films from Natural Mu...
Kashish Mulani, Saniya Mulla, Nikita Sawant, Kalyani Gardi, Bharatee Chaudhari, Vivekkumar Redasani,...
Film Forming Gels: A Review ...
Pradnya K Gangurde, Kajal A Choursiya, Saba Shaikh, Shardha Kandalkar, Khanderao Jadhav, Rishikesh B...
View more
A Review on Formulation and Evaluation of Effervescent Tablet ...
Deshmukh Komal, Narsale Somanath, Salve Bhumika, Chavan Rutuja, ...
Sustainable Shielding: Comparative Analysis of Edible Thin Films from Natural Mu...
Kashish Mulani, Saniya Mulla, Nikita Sawant, Kalyani Gardi, Bharatee Chaudhari, Vivekkumar Redasani,...
Film Forming Gels: A Review ...
Pradnya K Gangurde, Kajal A Choursiya, Saba Shaikh, Shardha Kandalkar, Khanderao Jadhav, Rishikesh B...
View more

Copyright © 2025 IJPS. All rights reserved